Nur für Premium Nutzer:
Jetzt 14 Tage kostenfrei testen
| Beispiel PDF herunterladen
Noch 3 von 3 Checks heute möglich
Mit dem Seobility Widget kannst Du Besuchern Deiner Website zeigen, wie gut Deine Seite SEO-optimiert ist. Das Widget zeigt immer den aktuellen SEO-Score Deiner Homepage/Startseite an.
Name | Wert |
---|---|
description | UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology. |
generator | Joomla! - Open Source Content Management |
viewport | width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no |
HandheldFriendly | true |
apple-mobile-web-app-capable | YES |
lang | en-gb |
content-type | text/html; charset=UTF-8 |
URL | ALT-Attribute | Titel |
---|---|---|
...lank/images/[email protected] | UroToday | |
...blank/images/[email protected] | Kein ALT-Attribut angegeben | |
...nk/images/video-channels/[email protected] | Kein ALT-Attribut angegeben | |
[email protected] | Kein ALT-Attribut angegeben | |
...ls/[email protected] | Kein ALT-Attribut angegeben | |
[email protected] | Kein ALT-Attribut angegeben | |
...mages/conferences-images/[email protected] | Kein ALT-Attribut angegeben | |
...s/conferences-images/[email protected] | Kein ALT-Attribut angegeben | |
...mages/[email protected] | Kein ALT-Attribut angegeben | |
...-images/[email protected] | Kein ALT-Attribut angegeben |
Überschriften Hierarchie | Inhalt |
---|---|
H2 | Videos |
H2 | Recent Conference Coverage |
H2 | Recent Physician-Scientist Review Articles |
H2 | Transformative Evidence |
H2 | Trials in Progress |
H3 | AUA 2025 |
H3 | Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives |
H3 | PSMA and Beyond 2025 |
H3 | ESMO 2024 Quick Takes |
H4 | Featured Videos |
H4 | Genomic Classifier in Prostate Cancer: High-Risk |
H4 | High-Risk Non-Muscle Invasive Bladder Cancer |
H4 | Advanced Bladder Cancer |
H4 | Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics |
H4 | Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC |
H4 | APCCC 2024 |
H4 | Latest Videos |
H4 | EMBARK |
H4 | Login |
Link | Attribute | Linktext |
---|---|---|
/privacy-policy.html | Privacy Policy | |
https://www.urotoday.com/ | UroToday IMG-ALT UroToday A-TITLE UroToday | |
/contact-us.html | Contact | |
/SimpleSignOn.modal | Login | |
/register.html | Sign Up Free | |
/peace-3-te.html | PEACE-3 Trial | |
/transformative-evidence/profo... | PROfound Trial | |
/transformative-evidence/ralu-... | The RALU Study: Treatment Considerations in the First Line Setting of mCRPC | |
/transformative-evidence/visio... | VISION Trial | |
/aranote-te.html | ARANOTE Trial | |
/transformative-evidence/the-a... | ARASENS Trial | |
/transformative-evidence/arami... | ARAMIS Trial | |
/transformative-evidence/embar... | EMBARK Trial | |
/transformative-evidence/cobra... | COBRA Trial | |
/transformative-evidence/clini... | CONDOR Trial | |
/transformative-evidence/clini... | OSPREY Trial | |
/n-803-te.html | ANKTIVA® | |
/transformative-evidence/bladd... | Bladder Cancer Detection | |
/transformative-evidence/core-... | CORE-001 Study | |
/ev-302-te.html | EV-302 | |
/video-lectures/immunotherapy-... | Immunotherapy in NMIBC | |
/centers-of-excellence.html | Centers of Excellence | |
/center-of-excellence/health-p... | Health Policy | |
/center-of-excellence/bladder-... | Bladder Cancer Ashish Kamat, MD A-TITLE Ashish Kamat, MD | |
/center-of-excellence/advanced... | Advanced Bladder Cancer Shilpa Gupta, MD A-TITLE Shilpa Gupta, MD | |
/center-of-excellence/trimodal... | Trimodality Therapy Leslie Ballas, MD A-TITLE Leslie Ballas, MD | |
/center-of-excellence/advanced... | Advanced Kidney Cancer Pedro Barata, MD, MSc A-TITLE Pedro Barata, MD, MSc | |
/center-of-excellence/kidney-c... | Endourology Jaime Landman, MD A-TITLE Jaime Landman, MD | |
/center-of-excellence/localize... | Localized Prostate Cancer Matthew R. Cooperberg, MD, MPH A-TITLE Matthew R. Cooperberg, MD, MPH | |
/center-of-excellence/decipher... | Decipher® Genomic Classifier | |
/center-of-excellence/imaging-... | Imaging Center Phillip Koo, MD A-TITLE Phillip Koo, MD | |
/center-of-excellence/mhspc.html | mHSPC Neeraj Agarwal, FASCO, MD A-TITLE Neeraj Agarwal, FASCO, MD | |
/center-of-excellence/nmcrpc.html | nmCRPC Zachary Klaassen, MD, MSc A-TITLE Zachary Klaassen, MD, MSc | |
/center-of-excellence/mcrpc-tr... | mCRPC Treatment A. Oliver Sartor, MD A-TITLE A. Oliver Sartor, MD | |
/center-of-excellence/mcrpc-wi... | mCRPC with Bone Metastasis | |
/center-of-excellence/psma-tar... | PSMA-Targeted Therapy | |
/center-of-excellence/advanced... | Advanced Prostate Cancer Zachary Klaassen, MD, MSc A-TITLE Zachary Klaassen, MD, MSc | |
/center-of-excellence/disparit... | Disparities: Social Determinants of Health Samuel L. Washington III, MD, MAS A-TITLE Samuel L. Washington III, MD, MAS | |
/center-of-excellence/translat... | Translational Science in Prostate Cancer Andrea Miyahira, Ph.D A-TITLE Andrea Miyahira, Ph.D | |
/center-of-excellence/women-in... | Women in Science Andrea Miyahira, Ph.D A-TITLE Andrea Miyahira, Ph.D | |
/center-of-excellence/upper-tr... | Upper Tract Urothelial Carcinoma Sam S. Chang, MD, MBA A-TITLE Sam S. Chang, MD, MBA | |
/center-of-excellence/testicul... | Testicular Cancer | |
/center-of-excellence/bladder-... | Bladder Health | |
/center-of-excellence/cauti.html | Urologic Catheters (Includes CAUTI) | |
/video-lectures.html | Videos | |
/video-lectures/conferences.html | Conferences | |
/video-lectures/exclusive-coll... | Exclusive Collaborations | |
/video-lectures/independent-ed... | Independent Medical Education | |
/video-lectures/covid-19.html | Covid-19 | |
/video-lectures/the-prostate-c... | The Prostate Cancer Foundation | |
/health-policy-in-urological-d... | Health Policy in Urological Diseases | |
/video-lectures/disparities-so... | Disparities: Social Determinants of Health | |
/video-lectures/practice-guide... | Practice Guidelines Reviews | |
/video-lectures/urologic-oncol... | Prostate Cancer | |
/video-lectures/urologic-oncol... | Bladder Cancer | |
/video-lectures/urologic-oncol... | Kidney Cancer | |
/video-lectures/urologic-oncol... | Upper Tract Urothelial Tumors | |
/video-lectures/urologic-oncol... | Textduplikat | Testicular Cancer |
/video-lectures/endourology-to... | Endourology | |
/video-lectures/pelvic-health-... | Pelvic Health & Reconstruction | |
/actionable-clinical-data/lg-i... | LG-IR NMIBC | |
/actionable-clinical-data/adst... | Adstiladrin® | |
/actionable-clinical-data/zirc... | ZIRCON | |
/trials-in-progress/bond-003-c... | BOND-003 Cohort P | |
/trials-in-progress/core-008-t... | CORE-008 | |
/trials-in-progress/immortal-t... | IMMORTAL | |
/trials-in-progress/pivot-006-... | PIVOT-006 | |
/trials-in-progress/radical-tr... | RadiCal | |
/trials-in-progress/samurai-tr... | SAMURAI | |
/trials-in-progress/aramon-tri... | ARAMON | |
/trials-in-progress/arasec-tri... | ARASEC | |
/trials-in-progress/arastep-tr... | ARASTEP | |
/trials-in-progress/clarify-tr... | CLARIFY | |
/trials-in-progress/eclipse-tr... | ECLIPSE | |
/trials-in-progress/escape-tri... | ESCAPE | |
/trials-in-progress/fort-trial... | FORT | |
/trials-in-progress/metanova-t... | METANOVA | |
/trials-in-progress/nrg-gu010-... | NRG-GU 0101 | |
/trials-in-progress/promise-pc... | PROMISE | |
/trials-in-progress/rtire-tria... | RTIRE | |
/trials-in-progress/secure-tri... | SECuRE | |
/trials-in-progress/shorter-tr... | SHORTER | |
/clinical-trials.html | Clinical Trials | |
/clinical-trials.html | Search Clinical Trials | |
/articles/urology-benign-and-m... | Urologic Oncology | |
/articles/urology-benign-and-m... | Men's Health | |
/articles/urology-benign-and-m... | Endourology & Stones | |
/pediatric-urology.html | Pediatric Urology | |
/covid-19-and-genitourinary-ca... | COVID-19 and Genitourinary Cancers | |
/articles/pelvic-health/pelvic... | Textduplikat | Pelvic Health & Reconstruction |
/conference-coverage.html | Conference Coverage | |
/conference-highlights/aua-202... | AUA 2025 | |
/conference-highlights/2025-uc... | PSMA and Beyond 2025 Conference | |
/conference-highlights/eau-202... | EAU 2025 | |
/conference-highlights/ses-aua... | SES AUA 2025 | |
/conference-highlights/2025-gu... | Thought Leaders 2025 | |
/conference-coverage.html | View All | |
/video-lectures/european-socie... | ESMO 2024 | |
https://www.urotoday.com/pcf.html | PCF | |
https://www.urotoday.com/ | Kein Text | |
/video-lectures.html | View all | |
/video-lectures/aua-2025.html | Kein Text | |
/transformative-evidence/bladd... | Real-World Data Improves NMIBC Risk Assessment with Blue Light Technology - Siamak Daneshmand & Boris Gershman | |
/video-lectures/aua-2025/video... | Platform Reduces Unnecessary Cystoscopies for Hematuria Patients - John Sfakianos | |
/aranote-te/videos/4807-aranot... | ARANOTE Study Shows Benefits of Deep PSA Response with Darolutamide - Neal Shore | |
/video-lectures/aua-2025.html | View all AUA 2025 videos | |
/video-lectures/leaders-in-rad... | Kein Text | |
/video-lectures/leaders-in-rad... | Imaging the Immune System: CD8 T-Cell Tracking for Cancer and Autoimmune Disease - Anna Wu | |
/video-lectures/leaders-in-rad... | Covalent Radioligands Advance Precision in Tumor Targeting - Andreas Goutopoulos | |
/video-lectures/leaders-in-rad... | Lead-212 Radiopharmaceuticals Offer Promise in Targeted Cancer Treatment - Volker Wagner | |
/video-lectures/leaders-in-rad... | View all Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives videos | |
/video-lectures/2025-ucsf-ucla... | Kein Text | |
/video-lectures/2025-ucsf-ucla... | Comparing Post-Treatment SPECT to PSMA PET for Radioligand Therapy Monitoring "Presentation" - Thomas Hope | |
/video-lectures/2025-ucsf-ucla... | Improving Outcomes with Combination Therapies for PSMA Radioligand Treatment "Presentation" - Michael Hofman | |
/video-lectures/2025-ucsf-ucla... | FAP and Nectin-4 Targeted Imaging and Therapy in Urothelial Cancer "Presentation" - Vadim Koshkin | |
/video-lectures/2025-ucsf-ucla... | View all PSMA and Beyond 2025 videos | |
/video-lectures/european-socie... | Kein Text | |
/video-lectures/european-socie... | Prostate Cancer QuickTakes ESMO 2024 - ARANOTE, PEACE-3, and SPLASH Trials - Oliver Sartor | |
/video-lectures/european-socie... | View all ESMO 2024 Quick Takes videos | |
/video-lectures/aua-2025/video... | Sasanlimab + BCG Improves Event-Free Survival in High-Risk NMIBC: CREST Study Results - Neal Shore | |
/video-lectures/aua-2025/video... | Evaluating Risk Stratification Models for Blue Light Cystoscopy in Bladder Cancer - Sia Daneshmand & Boris Gershman | |
/actionable-clinical-data/adst... | Streamlining Intravesical Therapy: Practical Insights for BCG-Unresponsive NMIBC - Patrick Hensley | |
/video-lectures/bladder-cancer... | Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines - Jay D. Raman & Yair Lotan | |
/actionable-clinical-data/lg-i... | Refining Risk in NMIBC: Intermediate Stratification, TURBT Quality, and Emerging Options - Katie Murray | |
/video-lectures/aua-2025/video... | The Details Are in the Core: Advancing Prostate Tissue Collection - James Wysock | |
/video-lectures/embark-trial/v... | EMBARK Trial: Treatment Options for High-Risk Biochemical Recurrence - Neal Shore | |
/video-lectures/practical-aspe... | First Patient Treated with Pluvicto™ in Pre-Chemotherapy Setting Following FDA Approval - Steven Finkelstein | |
/video-lectures/eau-2025/video... | Cretostimogene Grenadenorepvec Complete Response in BOND-003 Cohort C - Trinity Bivalacqua | |
/video-lectures/asco-gu-2025/v... | LEGEND Trial: EG-70 in BCG-Refractory Non-Muscle Invasive Bladder Cancer - John Taylor | |
/video-lectures/psma-targetedt... | FDA Approval of 177Lu-PSMA-617 for Taxane-Naive mCRPC - Oliver Sartor | |
/video-lectures/advanced-bladd... | A Case-Based Discussion on First-Line EV + Pembrolizumab for Metastatic Urothelial Carcinoma - Neal Shore | |
/actionable-clinical-data/lg-i... | ENVISION Trial Evaluates UGN-102 for Recurrent Low-Grade NMIBC Bladder Cancer - Sandip Prasad | |
/video-lectures/asco-gu-2025/v... | PREDICT Trial Investigates Biomarker-Guided Treatment for Advanced Prostate Cancer - Rana McKay | |
/video-lectures/localized-pros... | Advanced Imaging for Focal Therapy in Intermediate Risk Prostate Cancer - Matthew Cooperberg | |
/video-lectures/mcrpc-treatmen... | Revisiting HER2 as a Therapeutic Target in Prostate Cancer - Nicole Mavingire | |
/video-lectures/asco-gu-2025/v... | Real-World Data on Treatment Patterns After PSMA-Targeted Therapy in mCRPC - Oliver Sartor | |
/video-lectures/asco-gu-2025/v... | Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett | |
/video-lectures/asco-gu-2025/v... | Cretostimogene Expanded Access Program for BCG-Unresponsive Bladder Cancer - Sarah Psutka | |
/video-lectures/asco-gu-2025/v... | Real-World Safety Profiles of First-Line Therapies for Advanced Urothelial Carcinoma - Amanda Nizam | |
/video-lectures/asco-gu-2025/v... | Adjuvant Nivolumab in High-Risk Muscle Invasive Bladder Cancer Analysis Shows Improved Outcomes for Patients: CheckMate 274 - Matthew Galsky | |
/video-lectures/asco-gu-2025/v... | Registry Data Shows Risk Migration With Blue Light Cystoscopy - Alireza Ghoreifi & Siamak Daneshmand | |
/video-lectures/asco-gu-2025/v... | ARANOTE Trial Explores Darolutamide’s Role in High and Low-Volume Metastatic Prostate Cancer - Fred Saad | |
/video-lectures/asco-gu-2025/v... | ABLE-32 Trial Explores Nadofaragene Firadenovec for Intermediate-Risk NMIBC - Neal Shore | |
/actionable-clinical-data/adst... | Real-World Data on Nadofarogene Firadenovec for BCG-Unresponsive Bladder Cancer - Mark Tyson & Jacob Moyer | |
/video-lectures/mhspc/video/me... | Physician Decision Making & Combination Therapies in Metastatic Prostate Cancer - Neeraj Agarwal | |
/video-lectures/managing-renal... | Advancing Imaging Techniques for Indeterminate Renal Mass Diagnosis and Clinical Decision-Making - Sam Chang | |
/video-lectures/localized-pros... | CLARIFY Trial: Multiday 64Cu-SAR-bisPSMA PET Scans Refine Prostate Cancer Assessment - Luke Nordquist | |
/video-lectures/lower-urinary-... | RISE FOR HEALTH Study on Female Bladder Health - Ariana Smith | |
/video-lectures/suo-2024/video... | Utilizing Telehealth to Improve Access of Care of Patients with Bladder Cancer - Tracey Krupski | |
/video-lectures/suo-2024/video... | Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients - Eric Kim & Mark Sultan | |
/video-lectures/suo-2024/video... | Advancing Treatment for BCG-Unresponsive Bladder Cancer - Eugene Pietzak | |
/video-lectures/suo-2024/video... | Emerging Neoadjuvant Combinations for Muscle-Invasive Bladder Cancer - Mamta Parikh | |
/video-lectures/suo-2024/video... | PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson | |
/video-lectures/suo-2024/video... | BCG Unresponsive Bladder Cancer in 2024 - Ashish Kamat | |
/video-lectures/suo-2024/video... | BOND-003 Trial Results in BCG Unresponsive Non-muscle Invasive Bladder Cancer - Mark Tyson | |
/video-lectures/esmo-2024/vide... | 5-Year Survival Outcomes in Cisplatin-Ineligible Patients from EV-103 - Jonathan Rosenberg | |
/video-lectures/esmo-2024/vide... | Nectin-4 Expression Not Predictive of Response in Enfortumab Vedotin Therapy - Thomas Powles | |
/video-lectures/journal-club/v... | Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen | |
/actionable-clinical-data/adst... | 36-Month Efficacy of Nadofaragene in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Yair Lotan | |
/video-lectures/south-central-... | BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah | |
/video-lectures/esmo-2024/vide... | Belzutifan vs Everolimus Trial Data in Advanced RCC Care - Brian Rini | |
/video-lectures/artificial-int... | AI-Powered Prostate Cancer Risk Assessment Tool Validated for Low-risk and Active Surveillance - Andre Esteva | |
/video-lectures/advanced-bladd... | SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner | |
/video-lectures/esmo-2024/vide... | NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles | |
/video-lectures/esmo-2024/vide... | Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad | |
/video-lectures/genomic-classi... | Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard | |
/video-lectures/localized-pros... | Radiation Therapy Options for Localized Prostate Cancer Compared in Major Trial - Jason Efstathiou | |
/video-lectures/esmo-2024/vide... | PEACE 3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad | |
/video-lectures/localized-pros... | Proton Therapy vs IMRT in Prostate Cancer PARTIQoL Trial - Jason Efstathiou | |
/video-lectures/high-risk-non-... | SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden | |
/video-lectures/mcrpc-treatmen... | RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca | |
/video-lectures/esmo-2024/vide... | Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad | |
/video-lectures/nccn-prostate-... | Medicare Part D 2025 Reduces Out-of-Pocket Costs for Oral Prostate Cancer Treatments - David Morris | |
/video-lectures/navigating-can... | Financial Distress for GU Cancer Patients: Insights from CDC Survey - Laura Bukavina & Steven Leonard | |
/video-lectures/navigating-can... | Cancer-Related Financial Hardship Among Cancer Survivors: Research from the HINTS-SEER Survey - Apoorv Dhir & Rishi Sekar | |
/video-lectures/localized-pros... | PARTIQoL Trial: Proton Therapy vs IMRT for Localized Prostate Cancer - Jason Efstathiou | |
/video-lectures/genomic-classi... | Utilizing the Decipher® mRNA Score for Risk Stratification in mHSPC - David Morris and Ashley Ross | |
/video-lectures/esmo-2024/vide... | PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal | |
/video-lectures/esmo-2024/vide... | UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad | |
/video-lectures/esmo-2024/vide... | EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore | |
/video-lectures/esmo-2024/vide... | ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad | |
/video-lectures/esmo-2024/vide... | PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel | |
/video-lectures/esmo-2024/vide... | SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi | |
/video-lectures/esmo-2024/vide... | Fecal Microbiota Transplant Boosts Immunotherapy in Metastatic Renal Cell Carcinoma in TACITO-II Trial - Chiara Ciccarese | |
/video-lectures/esmo-2024/vide... | Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky | |
/video-lectures/esmo-2024/vide... | PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman | |
/video-lectures/esmo-2024/vide... | COTRIMS Trial Shows High Cure Rates with RPLND in Stage IIA/B Seminoma - Axel Heidenreich | |
/video-lectures/esmo-2024/vide... | AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer - Andrea Apolo | |
/video-lectures/esmo-2024/vide... | SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor | |
/video-lectures/esmo-2024/vide... | TiNivo-2 Trial Results in Advanced Renal Cell Carcinoma Treatment - Toni Choueiri | |
/video-lectures/esmo-2024/vide... | Genetic Profiles in Early vs. Late Stage Urothelial Cancer - Dag Stormoen | |
/video-lectures/bcan-think-tan... | Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li | |
/video-lectures/journal-club/v... | Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen | |
/video-lectures/lower-urinary-... | The Rise of FRU: How Functional Urology Intersects with Reconstructive Urology - Brian J. Flynn | |
/video-lectures/localized-pros... | Transperineal vs Transrectal Prostate Biopsy: Trial Findings and Discussion - Badar Mian | |
/video-lectures/endourology-to... | Robotic Mini-PCNL and Ureteroscopy: Advancing Kidney Stone Treatment "Presentation" - Jaime Landman | |
/video-lectures/pet-psma-imagi... | Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett | |
/video-lectures/pet-psma-imagi... | CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET - Neal Shore | |
/video-lectures/lower-urinary-... | COURAGE Trial: Vibegron for BPH Patients with Persistent OAB Symptoms - David Staskin | |
/video-lectures/advanced-bladd... | EV-302 Trial Establishes Treatment Standard for Urothelial Carcinoma - Daniel Petrylak | |
/video-lectures/mcrpc-treatmen... | Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak | |
/video-lectures/leaders-in-rad... | Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff | |
/video-lectures/the-prostate-c... | Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo | |
/video-lectures/cancer-or-not-... | Reservations About a Nomenclature Change for Gleason Grade 1 Prostate Cancer "Presentation" - Adam Kibel | |
/video-lectures/bladder-cancer... | Trimodal Therapy in Urothelial vs Non-Urothelial Bladder Cancer - Mario de Angelis | |
/video-lectures/precision-medi... | Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner | |
/video-lectures/clinical-trial... | Urologic Oncology Clinical Trials: Size, Scope, and Impact - Kristian Stensland | |
/video-lectures/bladder-health... | Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment - Beyond the Abstract | |
/video-lectures/navigating-can... | Reducing Prescription Drug Costs: 4 Online Tools for Urology Patients - Benjamin Pockros | |
/video-lectures/upper-tract-ur... | FGFR3 Inhibition for Upper Tract Urothelial Cancer: Phase 1b Trial Results - Surena Matin | |
/video-lectures/advanced-kidne... | Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia | |
/video-lectures/asco-2024/vide... | PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi | |
/video-lectures/health-policy-... | Post-Prostatectomy Care: Variability in Treatment for Lymph Node Positive Prostate Cancer - Daniel Triner | |
/video-lectures/bladder-cancer... | dMMR and MSI-H in Urothelial Carcinoma: Prevalence and Treatment Implications - Elias Chandran | |
/video-lectures/mcrpc-treatmen... | Meta-Analysis Evaluates Cardiovascular Risks of AR Inhibitors in Prostate Cancer - Omar El-Taji & Ashwin Sachdeva | |
/video-lectures/renal-cancer/v... | Functional Renal Imaging and Advances in Kidney Cancer Detection - Shankar Siva | |
/video-lectures/asco-2024/vide... | CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith | |
/video-lectures/women-in-scien... | Breaking Barriers in Cancer Treatment and Women's Leadership in Oncology - Ulka Vaishampayan | |
/video-lectures/the-prostate-c... | PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff | |
/video-lectures/the-prostate-c... | Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen | |
/video-lectures/genomic-classi... | 2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen | |
/video-lectures/bladder-cancer... | Bladder-Sparing Chemoradiation for Localized Bladder Cancer: Addressing the Unmet Need - Brent Rose | |
/video-lectures/aua-2024/video... | SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten | |
/video-lectures/advanced-prost... | IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb | |
/video-lectures/advanced-prost... | Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh | |
/video-lectures/precision-medi... | Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal | |
/video-lectures/the-prostate-c... | ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan | |
/video-lectures/asco-2024/vide... | ARAMIS Trial: PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans | |
/video-lectures/non-muscle-inv... | Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial - Yair Lotan | |
/video-lectures/mhspc/video/me... | Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski | |
/video-lectures/mcrpc-treatmen... | OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan | |
/video-lectures/mcrpc-treatmen... | Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi | |
/video-lectures/advanced-prost... | COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo | |
/video-lectures/advanced-prost... | Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Re... | |
/video-lectures/advanced-bladd... | Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions - Matthew Galsky & Neal Shore | |
/video-lectures/asco-2024/vide... | CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li | |
/video-lectures/localized-pros... | Prostate Cancer Knowledge and Screening Barriers in Northern Tanzania: A Community-Based Study - Blandina Mmbaga & Nicholas Ngowi | |
/video-lectures/bladder-cancer... | Apalutamide for Preventing Bladder Cancer Recurrence: A Proof-of-Principle Trial - Edward Messing | |
/video-lectures/advanced-prost... | UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova | |
/video-lectures/disparities-so... | Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems - Isla Garraway | |
/video-lectures/apccc-2024/vid... | Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin | |
/video-lectures/localized-pros... | Testosterone Recovery After ADT: Timing, Predictive Factors, and Clinical Implications - Pierre Blanchard | |
/video-lectures/advanced-prost... | Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt | |
/video-lectures/imaging-prosta... | COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore | |
/video-lectures/non-muscle-inv... | Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie | |
/video-lectures/apccc-2024/vid... | Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis | |
/video-lectures/lower-urinary-... | Risk Classification for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Using Machine Learning Based Predictions - Beyond the Abstract | |
/video-lectures/apccc-2024/vid... | The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo | |
/video-lectures/bladder-cancer... | Balancing Bladder Preservation with Effective Treatment in Cancer Care - Petros Grivas | |
/video-lectures/ibcg-aua-2024-... | Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla | |
/video-lectures/non-muscle-inv... | Integrating Nadofaragene Firadenovec into Clinical Practice for Non-Muscle Invasive Bladder Cancer Treatment - Ashish Kamat | |
/video-lectures/treatments-in-... | BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson | |
/video-lectures/aua-2024/video... | VA BRAVO 2 Study: Blue Light Cystoscopy Improves Outcomes in NMIBC Patients in Equal Access Setting - Stephen B Williams | |
/video-lectures/non-muscle-inv... | Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer AUA/SUO Guideline - 2024 Amendment - Jeffrey Holzbeierlein | |
/video-lectures/eau-2024/video... | Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians - Cora Sternberg | |
/video-lectures/eau-2024/video... | Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal | |
/video-lectures/advanced-bladd... | Preclinical Study Evaluates Enfortumab Vedotin and Sacituzumab Govitecan with Radiation for Bladder Cancer - Kent Mouw | |
/video-lectures/eau-2024/video... | Local Therapy in mHSPC: Who Does Really Benefit? - Alberto Bossi | |
/video-lectures/advanced-bladd... | Genomic Tumor Correlates of Response to Trimodal Therapy for Muscle-Invasive Bladder Cancer - Sophia Kamran | |
/video-lectures/embark-trial/v... | The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore | |
/video-lectures/disparities-so... | The Future State of Race & Ethnicity in Urology: Urology Workforce Projection from 2021-2061 - Efe Chantal Ghanney Simons & Ashley Appleton | |
/video-lectures/prostate-cance... | A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - Beyond the Abstract | |
/video-lectures/localized-pros... | Novel 18-Gene Urine Test Improves Detection of Clinically Significant Prostate Cancer - Jeffrey Tosoian | |
/video-lectures/non-muscle-inv... | Patient-Driven Outcomes in the CISTO Trial for High-Grade Non-Muscle Invasive Bladder Cancer - Angela Smith & John Gore | |
/video-lectures/enhancing-andr... | Non-Metastatic Castration-Resistant Prostate Cancer in the Era of PSMA PET Imaging - Aaron Berger | |
/video-lectures/the-continuum-... | Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses | |
/video-lectures/the-continuum-... | Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer | |
/video-lectures/the-continuum-... | Best Practices for Successfully Implementing Triplet Therapy in mHSPC - Christopher Pieczonka | |
/video-lectures/eau-2024/video... | Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi | |
/video-lectures/eau-2024/video... | Advancements in Cutting-Edge SABR Therapy for Oligometastatic Kidney Cancer - Shankar Siva | |
/video-lectures/psma-ucsf-ucla... | Patient Selection for Radioligand Therapy: Case Study Discussion - Amir Iravani & Evan Yu | |
/actionable-clinical-data/adst... | Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis | |
/video-lectures/health-policy-... | Topical Estrogen Therapy in Preventing Recurrent UTIs in Women - Rachael Sussman, Charlotte Houston with Ruchika Talwar | |
/video-lectures/journal-club/v... | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen | |
/video-lectures/bladder-cancer... | Sequential Gemcitabine and Docetaxel Shows Promise for Intermediate-Risk NMIBC - Vignesh Packiam | |
/video-lectures/non-muscle-inv... | Age Alone Should Not Preclude BCG Therapy in NMIBC - Ashish Kamat | |
/video-lectures/prostate-cance... | Novel Computational Approach Identifies NME2-MYC Axis as Biomarker and Therapeutic Target in Enzalutamide-Resistant CRPC - Antonina Mitrofanova | |
/video-lectures/asco-gu-2024/v... | Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore | |
/video-lectures/prostate-cance... | Advancing Personalized Medicine: Examining Trop2 as a Biomarker to Stratify Prostate Cancer Patient Risk - Tanya Stoyanova | |
/video-lectures/mcrpc-treatmen... | COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emman... | |
/video-lectures/state-of-the-a... | The Use of Imaging in Staging Localized Prostate Cancer: A Case Study on High-Risk Localized Prostate Cancer - Zachary Klaassen | |
/actionable-clinical-data/adst... | Treatment Options Expand for BCG Unresponsive Bladder Cancer - Mark Tyson | |
/video-lectures/treatments-in-... | PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mar... | |
/actionable-clinical-data/adst... | Establishing Nadofaragene Firadenovec in a Large Urology Practice - Daniel Canter | |
/actionable-clinical-data/adst... | Real-World Use of Nadofaragene Firadenovec - Siamak Daneshmand | |
/video-lectures/advanced-prost... | Patient Selection for PSMA Radioligand Therapy - Ephraim Parent | |
/video-lectures/psma-ucsf-ucla... | Access to Cutting-Edge Therapies and Clinical Trials in the VA- Matthew Rettig | |
/video-lectures/asco-gu-2024/v... | Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor | |
/video-lectures/psma-targetedt... | Radioligand Therapy's Role in Treating mCRPC - Oliver Sartor | |
/video-lectures/psma-ucsf-ucla... | Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais | |
/video-lectures/advanced-prost... | Distinct Mesenchymal Cell States Mediate Prostate Cancer Progression - Massimo Loda | |
/video-lectures/health-policy-... | Access and Utilization of Healthcare by Adults with Spina Bifida - Lindsay Hampson & Alejandro Lopez | |
/video-lectures/health-policy-... | Comparing Cost-Effectiveness of Surgery, Radiation, and Chemo for Seminoma - Daniel Joyce | |
/video-lectures/testicular-can... | Testicular Cancer Survivors Find Community and Healing Through Foundation and Patient Summit - Connor O'Leary & Charles Freeman McCluskey | |
/video-lectures/advanced-prost... | Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen | |
/video-lectures/esmo-2023/vide... | Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu | |
/video-lectures/health-policy-... | Socioeconomic Disparities Drive Alarming Racial Gaps in Kidney Cancer Patient Survival Rates - Nirmish Singla | |
/video-lectures/the-prostate-c... | Novel Research Illuminates How CXCR7 Protein Interactions Promote Growth of Neuroendocrine Prostate Cancer - Jindan Yu | |
/video-lectures/prostate-cance... | How Chemotherapy Drives Metastasis By Causing Tumor Cells to Become Significantly More Mobile - Sarah Amend | |
/video-lectures/genomic-classi... | Deciphering Prostate Cancer: How Genomic Biomarkers are Shaping Treatment Decisions - Paul Nguyen | |
/video-lectures/pcf-2023/video... | Exploring the Multifaceted Role of a Medical Oncologist in Advanced Prostate Cancer Care and Management - Alicia Morgans | |
/video-lectures/mcrpc-treatmen... | Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly | |
/video-lectures/precision-medi... | Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard | |
/video-lectures/pcf-2023/video... | INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence - Neha Vapiwala | |
/video-lectures/the-prostate-c... | The Complex Web of SPOP Mutations and STING1 Signaling in Prostate Cancer - Patrick Pilié | |
/video-lectures/esmo-2023/vide... | Innovative Prostate Cancer Therapy Insights Unveiled in ESMO 2023 Meeting - Alan Bryce | |
/video-lectures/esmo-2023/vide... | The LITESPARK-013 Trial and Belzutifan's Optimal Dose for Treating Metastatic Renal Cell Carcinoma - Neeraj Agarwal | |
/video-lectures/beyond-androge... | Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming | |
/video-lectures/beyond-androge... | Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi | |
/video-lectures/genomic-classi... | Correlation and Validation of Gene Expression Classifiers in Prostate Cancer: A Large-Scale Study - Daniel Spratt | |
/video-lectures/esmo-2023/vide... | PSMAfore Study Unveils Game-Changing Results for Prostate Cancer Treatment - Oliver Sartor | |
/video-lectures/health-policy-... | Prostate Cancer Drug Costs: A Complex Landscape of Out-of-Pocket Expenses - Benjamin Pockros | |
/video-lectures/health-policy-... | Innovation in Oncology Drug Pricing: A Comparative Study of Savings Potential - Ruchika Talwar & Brian Cortese | |
/video-lectures/bladder-cancer... | Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross | |
/video-lectures/asco-2023/vide... | A Breakthrough in Urothelial Cancer Treatment: Enfortumab Vedotin Combination Therapy - Expert Insights and Impressive Response Rates - Jonathan E. Rosenberg | |
/video-lectures/asco-2023/vide... | The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi | |
/video-lectures/advanced-bladd... | Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jaso... | |
/video-lectures/patient-journe... | Choosing JELMYTO®: A Patient's Journey Through Less Invasive Upper Tract Urothelial Carcinoma Treatment - Tom Murphy | |
/video-lectures/asco-2023/vide... | Beyond BRCA-1 and 2: The Impact of the TALAPRO-2 Study on Prostate Cancer Care - Cora Sternberg | |
/video-lectures/asco-gu-2023/v... | Exploring Erdafitinib: A Breakthrough in Non-Muscle Invasive Bladder Cancer Treatment - Siamak Daneshmand | |
/video-lectures/women-in-scien... | Personal Passion Fuels Progress: Unraveling Prostate Cancer Aggressiveness in Black Men - Leanne Woods-Burnham | |
/video-lectures/non-muscle-inv... | Gene Therapy for NMIBC: A New Era of Treatment - Colin Dinney | |
/video-lectures/renal-cancer/v... | Enhancing Patient-Centered Communication in Small Renal Mass Management - Kathryn Hacker Gessner | |
/video-lectures/aua-2023/video... | Journal of Urology Open Plus - Revolutionizing Access and Innovation in Urology Research - John W. Davis | |
/video-lectures/aua-2023/video... | Improving Primary Prostate Cancer Diagnosis Through Risk Stratified Screening: a European Perspective - Sigrid Carlsson | |
/video-lectures/advanced-kidne... | Combining Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma, Exploring Novel Therapy Options - Toni Choueiri | |
/video-lectures/genomic-classi... | Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu | |
/video-lectures/aua-2023/video... | Insights into the AUA Guidelines for Upper Tract Urothelial Carcinoma: Standardizing Diagnosis and Treatment for Better Patient Outcomes - Jonathan A. Coleman | |
/video-lectures/localized-pros... | ProtecT Trial Reveals New Insights for Prostate Cancer Treatment: Implications for Low-Risk vs. High-Risk Patients - David Penson | |
/video-lectures/aua-2023/video... | Assessing the Effectiveness of N-803 for BCG Unresponsive Bladder Cancer: Promising Complete Remission Rates and Improved Long-Term Response - Patrick Soon-S... | |
/video-lectures/the-prostate-c... | PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armst... | |
/video-lectures/bladder-cancer... | Targeting the HLA-E/NKG2A Axis to Overcome BCG Resistance in NMIBC, BCAN Translational Clinical Trial Award - Amir Horowitz | |
/video-lectures/asco-gu-2023/v... | Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore | |
/video-lectures/asco-gu-2023/v... | Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad | |
/video-lectures/women-in-scien... | The Role of Awareness and Support in Elevating Women in Science - Kristen Scarpato & Svetlana Avulova | |
/video-lectures/advanced-prost... | Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis | |
/video-lectures/esmo-2022/vide... | Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi | |
/video-lectures/genomic-classi... | Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard | |
/video-lectures/apccc-2024/vid... | A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore | |
/video-lectures/asco-2022/vide... | CAR T and Cellular-Based Therapies - Vivek Narayan | |
/video-lectures/esmo-2022/vide... | The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore | |
/video-lectures/ibcg-aua-2024-... | Timing of Radical Cystectomy in BCG Unresponsive Disease - Patrick Hensley | |
/video-lectures/aua-2022/video... | Women in Urologic Oncology - Anne K. Schuckman | |
/video-lectures/asco-2022/vide... | Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans | |
/video-lectures/asco-2022/vide... | Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff | |
/video-lectures/asco-2022/vide... | Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel | |
/video-lectures/asco-2022/vide... | The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff | |
/video-lectures/aua-2022/video... | Bladder Cancer Highlights - Stephen Williams | |
/video-lectures/apccc-2024/vid... | APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu | |
/video-lectures/apccc-2024/vid... | Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans | |
/video-lectures/esmo-2022/vide... | EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advan... | |
/video-lectures/esmo-2022/vide... | A Urologist's Perspective on the PROpel Trial, Olaparib and Abiraterone versus Abiraterone Alone, in the First-Line Metastatic Castration-Resistant Prostate ... | |
/video-lectures/genomic-classi... | An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abira... | |
/center-of-excellence/imaging-... | Smarter Screening In Prostate Cancer - Sigrid Carlsson | |
/video-lectures/asco-2022/vide... | CheckMate 214: A Deep Dive into Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma - David Cella | |
/video-lectures/upper-tract-ur... | Evaluating the Impact of Variant Histology Pathologic Diagnosis on Survival Outcomes in Patients with Upper Tract Urothelial Carcinoma - Wesley Yip | |
/video-lectures/aua-2022/video... | Upper Tract Urothelial Carcinoma Highlights - Nima Almassi | |
/video-lectures/mhspc/video/me... | A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore | |
/video-lectures/mhspc/video/me... | Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal | |
/video-lectures/mhspc/video/me... | Darolutamide Approved for Patients with mHSPC - Charles Ryan | |
/video-lectures/ibcg-aua-2024-... | The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefke... | |
/video-lectures/imaging-prosta... | First Standardized Framework Measuring PSMA PET/CT Response in Metastatic Castration‑Resistant Prostate Cancer - Wolfgang Fendler and Andrei Gafita | |
/video-lectures/advanced-prost... | The 6th Global Summit On Precision Diagnosis and Treatment Of Prostate Cancer - Faina Shtern, The AdMe Tech Foundation | |
/video-lectures/embark-trial/v... | The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prosta... | |
/video-lectures/practical-mana... | Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo | |
/video-lectures/upper-tract-ur... | Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101 in the OLYMPUS Trial - John Gore | |
/video-lectures/bladder-cancer... | Management Trends & Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma, the USC Experience - Anirban Mitra | |
/video-lectures/upper-tract-ur... | Comparative Effectiveness of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma- Jeffrey Holzbeierlein | |
/video-lectures/upper-tract-ur... | Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia | |
/video-lectures/intermittent-c... | Convatec GentleCath™ Glide No-Touch Catheters - Diane Newman | |
/video-lectures/intermittent-c... | Uncoated Catheters - Diane Newman | |
/video-lectures/intermittent-c... | Closed Catheters Systems - Diane Newman | |
/video-lectures/crpc-w-bone-me... | Treatment Sequencing with Radium-223 in Symptomatic Disease - Fred Saad | |
/video-lectures/apccc-2024/vid... | Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan | |
/video-lectures/aua-2022/video... | Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin | |
/video-lectures/intermittent-c... | Self Intermittent Catheters Types - Diane Newman | |
/video-lectures/bladder-cancer... | Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams | |
/video-lectures/psma-targetedt... | A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore | |
/video-lectures/aua-2022/video... | Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen | |
/video-lectures/aua-2022/video... | The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore | |
/video-lectures/apccc-2024/vid... | PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad | |
/video-lectures/asco-gu-2022/v... | Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans | |
/video-lectures/13th-uro-oncol... | Future Perspectives in Prostate Imaging in Developing Countries - Ronaldo Hueb Baroni | |
/video-lectures/localized-pros... | Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz | |
/video-lectures/bladder-cancer... | Microbiome Research in Bladder Cancer - Laura Bukavina | |
/video-lectures/advanced-bladd... | Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukd... | |
/video-lectures/13th-uro-oncol... | The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares | |
/video-lectures/prostate-cance... | Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp | |
/video-lectures/intermittent-c... | Evidence Supporting the Use of Urinary Catheters for Intermittent Catheterization - Diane Newman | |
/video-lectures/13th-uro-oncol... | Lessons Learned in the STAMPEDE Trial - Nicholas James | |
/video-lectures/disparities-so... | Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain & Christopher Dee | |
/video-lectures/overactive-bla... | Mechanistic Pathway Through Which Saphenous Nerve Stimulation Can Modulate Bladder Function - Paul Yoo | |
/video-lectures/overactive-bla... | Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder - Anne Agur | |
/video-lectures/imaging-prosta... | Radiotherapy Guided by PSMA PET Molecular Imaging - Juan Galvis Serrano | |
/video-lectures/practical-aspe... | Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris | |
/video-lectures/practical-aspe... | Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo | |
/center-of-excellence/imaging-... | Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen | |
/video-lectures/genomic-classi... | The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra | |
/video-lectures/advanced-prost... | Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank... | |
/video-lectures/bladder-cancer... | The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran | |
/video-lectures/bladder-cancer... | Biological Pathways in Urothelial Carcinoma - Carissa Chu | |
/video-lectures/upper-tract-ur... | Long-Term Safety and Durability to Non-Surgical Treatment Instillation of UGN-101, Mitomycin-Containing Reverse Thermal Gel for Low-Grade Upper Tract Urothel... | |
/video-lectures/bladder-cancer... | Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial | |
/video-lectures/advanced-kidne... | The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic | |
/video-lectures/asco-gu-2022/v... | Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma - Wesley Yip | |
/video-lectures/practical-aspe... | Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris | |
/center-of-excellence/imaging-... | Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne | |
/video-lectures/psma-targetedt... | Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris | |
/video-lectures/apccc-2024/vid... | The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen | |
/video-lectures/asco-gu-2022/v... | Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg | |
/video-lectures/asco-gu-2022/v... | Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer - Brian Gonzalez | |
/video-lectures/precision-medi... | Pluvicto The First Targeted Radioligand Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer FDA Approved - Charles Ryan and Alicia Morgans | |
/video-lectures/upper-tract-ur... | Molecular Biomarkers in Upper-Tract Urothelial Carcinoma - Janet Kukreja | |
/video-lectures/localized-pros... | Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks | |
/video-lectures/asco-gu-2022/v... | The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial... | |
/video-lectures/asco-gu-2022/v... | Treatment and Survival Differences in Patients With Urothelial Vs. Nonurothelial Bladder & Upper Tract Carcinomas - Jeanny Aragon-Ching | |
/video-lectures/localized-pros... | Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein | |
/video-lectures/asco-gu-2022/v... | The Next Wave of Novel Radiopharmaceuticals - Shahneen Sandhu | |
/video-lectures/psma-targetedt... | Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar | |
/video-lectures/advanced-kidne... | KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri | |
/video-lectures/asco-gu-2022/v... | DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky | |
/video-lectures/genomic-classi... | Validation of Performance of the Decipher® Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0... | |
/video-lectures/aua-2022/video... | Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi | |
/video-lectures/imaging-prosta... | PSMA PET/CT Imaging Indications in Prostate Cancer - Neal Shore & Oliver Sartor | |
/video-lectures/bladder-cancer... | Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron | |
/video-lectures/bladder-cancer... | Quality of Life for Patients Undergoing Radical Cystectomy - Bernard Bochner | |
/video-lectures/localized-pros... | Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell | |
/video-lectures/bladder-cancer... | Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka | |
/video-lectures/advanced-bladd... | Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack | |
/video-lectures/bladder-cancer... | Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye | |
/video-lectures/expert-voice/v... | From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom | |
/video-lectures/bladder-cancer... | Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black | |
/video-lectures/nccn-prostate-... | NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and... | |
/video-lectures/non-muscle-inv... | Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki | |
/video-lectures/crpc-w-bone-me... | Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan | |
/video-lectures/pcf-2021/video... | NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff | |
/video-lectures/crpc-w-bone-me... | A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metas... | |
/video-lectures/mcrpc-treatmen... | Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor | |
/video-lectures/lugpa-2024/vid... | PSMA Imaging - Is Conventional Imaging Obsolete - Steven Rowe | |
/video-lectures/bladder-cancer... | Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf | |
/video-lectures/lugpa-2024/vid... | Urogynecology Controversies: Female Pelvic Medicine and Reconstructive Surgery - Briana Walton | |
/video-lectures/localized-pros... | Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen | |
/video-lectures/lugpa-2024/vid... | Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo | |
/video-lectures/psma-academy/v... | Understanding Physiological PSMA Biodistribution - Jeremie Calais | |
/video-lectures/pcf-2021/video... | Women in Science and The Prostate Cancer Foundation - Amina Zoubeidi | |
/video-lectures/mhspc/video/me... | Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne | |
/video-lectures/bladder-cancer... | The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey | |
/video-lectures/genomic-classi... | High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack | |
/video-lectures/endourology-to... | Single-Use Disposable Cystoscopy - Roger Dmochowski, David Chaikin, & Vijay Goli | |
/video-lectures/esmo-2021/vide... | Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello | |
/video-lectures/bladder-cancer... | Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia | |
/video-lectures/crpc-w-bone-me... | Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor | |
/video-lectures/advanced-prost... | Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio | |
/video-lectures/upper-tract-ur... | Antegrade Endoscopic Upper Tract Approaches - Ryan Hsi | |
/video-lectures/esmo-2021/vide... | Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke | |
/video-lectures/upper-tract-ur... | Upper Tract Urothelial Carcinoma - Clinical Case Management in High-Risk Disease - Sima Porten | |
/video-lectures/esmo-2021/vide... | PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris | |
/video-lectures/esmo-2021/vide... | Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor | |
/video-lectures/non-muscle-inv... | The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz | |
/video-lectures/nmcrpc/video/m... | Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore | |
/video-lectures/esmo-2021/vide... | STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostat... | |
/video-lectures/lower-urinary-... | A Novel Sublingual Vaccine for Prevention of Recurrent Urinary Tract Infections in Women - J. Curtis Nickel | |
/video-lectures/esmo-2021/vide... | Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi | |
/video-lectures/esmo-2021/vide... | Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Kar... | |
/video-lectures/lower-urinary-... | The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber | |
/video-lectures/bladder-cancer... | Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid | |
/video-lectures/asco-2021/vide... | Impact of Age on Castration Rates from The HERO Study – Michael Cookson | |
/video-lectures/upper-tract-ur... | Risk Stratification of Upper Tract Urothelial Carcinoma - Doug Scherr | |
/video-lectures/crpc-w-bone-me... | Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abst... | |
/video-lectures/practical-aspe... | The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris | |
/video-lectures/localized-pros... | Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher® Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Al... | |
/video-lectures/localized-pros... | When to Add ADT to Early or Late Salvage Radiation - Dan Spratt | |
/video-lectures/localized-pros... | Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt | |
/video-lectures/snmmi-curricul... | Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi | |
/video-lectures/advanced-bladd... | Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo | |
/video-lectures/mcrpc-treatmen... | The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff | |
/video-lectures/asco-2021/vide... | Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor | |
/video-lectures/psma-targetedt... | The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris | |
/video-lectures/overactive-bla... | The OAB Clinical Care Pathway Mobile APP - Stephen Kraus | |
/video-lectures/upper-tract-ur... | Management and Challenges of Low Grade Upper Tract Urothelial Carcinoma - Surena Matin | |
/video-lectures/bladder-cancer... | The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak | |
/video-lectures/psma-targetedt... | Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu | |
/video-lectures/localized-pros... | PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu | |
/video-lectures/bladder-cancer... | The Management of Primary Carcinoma of The Urethra - Reza Mehrazin | |
/video-lectures/journal-club/v... | 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen | |
/video-lectures/crpc-w-bone-me... | Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone | |
/video-lectures/asco-2021/vide... | Defining the Standard of Therapy for First-Line mHSPC - Lisa Horvath | |
/video-lectures/bladder-cancer... | Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova | |
/video-lectures/upper-tract-ur... | How I Use Jelmyto™ - Karim Chamie | |
/video-lectures/asco-2021/vide... | 177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris | |
/video-lectures/journal-club/v... | A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate... | |
/video-lectures/imaging-prosta... | PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris | |
/video-lectures/testicular-can... | Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen | |
/video-lectures/upper-tract-ur... | Upper Tract Urothelial Carcinoma - Clinical Case Management – Jonathan Coleman | |
/video-lectures/cardiovascular... | Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun | |
/video-lectures/non-muscle-inv... | The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker | |
/video-lectures/mcrpc-treatmen... | Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit | |
/video-lectures/mhspc/video/me... | Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal | |
/video-lectures/testicular-can... | Survivorship in Testicular Cancer - Mary Dunn | |
/video-lectures/advanced-bladd... | Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal | |
/video-lectures/asco-gu-2021-b... | Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar | |
/video-lectures/non-muscle-inv... | Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak | |
/video-lectures/lower-urinary-... | Facing Pelvic Pain - Elise De | |
/video-lectures/asco-gu-2021-p... | Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea | |
/video-lectures/advanced-prost... | Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross | |
/video-lectures/lower-urinary-... | The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim | |
/video-lectures/genomic-classi... | A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt | |
/video-lectures/asco-gu-2021-p... | Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor | |
/video-lectures/mcrpc-treatmen... | Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal | |
/video-lectures/bladder-cancer... | Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner | |
/video-lectures/endourology-to... | Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano | |
/video-lectures/mcrpc-treatmen... | NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff | |
/video-lectures/imaging-prosta... | The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope | |
/video-lectures/prostate-cance... | Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan ... | |
/video-lectures/molecular-diag... | Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron | |
/video-lectures/mcrpc-treatmen... | The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans | |
/video-lectures/non-muscle-inv... | Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni | |
/video-lectures/imaging-prosta... | 68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope | |
/video-lectures/expert-voice/v... | Racial Differences in Genomic Profiling in Prostate Cancer - Brandon Mahal | |
/video-lectures/nmcrpc/video/m... | Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi | |
/video-lectures/snmmi-curricul... | Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell | |
/video-lectures/advanced-bladd... | Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III | |
/video-lectures/mcrpc-treatmen... | Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant ... | |
/video-lectures/localized-pros... | An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener | |
/video-lectures/mcrpc-treatmen... | Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans | |
/video-lectures/molecular-diag... | The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor | |
/video-lectures/advanced-bladd... | The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo | |
/video-lectures/precision-medi... | DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao | |
/video-lectures/non-muscle-inv... | Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney | |
/video-lectures/precision-medi... | PSMA-directed Therapy - Scott Tagawa and Michael Morris | |
/video-lectures/advanced-bladd... | JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer ... | |
/video-lectures/mhspc/video/me... | Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu | |
/video-lectures/bladder-cancer... | Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin | |
/video-lectures/bladder-cancer... | A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang | |
/video-lectures/bladder-cancer... | Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua | |
/video-lectures/bladder-cancer... | Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid | |
/video-lectures/patient-voice/... | In His Own Voice: His 15-Year Journey with Advanced Prostate Cancer - Steve Poggi | |
/video-lectures/bladder-cancer... | A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Pe... | |
/video-lectures/advanced-prost... | HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore | |
/video-lectures/mcrpc-treatmen... | Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida | |
/video-lectures/precision-medi... | Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen | |
/video-lectures/mcrpc-treatmen... | IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Swe... | |
/video-lectures/bladder-cancer... | Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks | |
/video-lectures/mcrpc-treatmen... | Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor | |
/video-lectures/expert-voice/v... | In Pursuit of Patient-Centered Care - Karen Knudsen | |
/video-lectures/patient-voice/... | Making Your Treatment Decision - Prostate Cancer Patient Interview with Andy Schwartz | |
/video-lectures/crpc-w-bone-me... | Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith | |
/video-lectures/covid-19-and-g... | NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer | |
/video-lectures/covid-19-and-g... | NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans | |
/video-lectures/nmcrpc/video/m... | Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore | |
/video-lectures/mcrpc-treatmen... | The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran | |
/video-lectures/upper-tract-ur... | Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle | |
/video-lectures/clinical-trial... | Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz | |
/video-lectures/mcrpc-treatmen... | CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi | |
/video-lectures/bladder-cancer... | A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar | |
/video-lectures/psma-targetedt... | The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris | |
/video-lectures/advanced-kidne... | First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang | |
/center-of-excellence/imaging-... | A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran | |
/video-lectures/mcrpc-treatmen... | Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor | |
/video-lectures/molecular-diag... | Genetic Counseling in Prostate Cancer - Brittany Szymaniak | |
/video-lectures/nmcrpc/video/m... | Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad | |
/video-lectures/expert-voice/v... | Clinical Trials: Another Treatment Option for Patients - Tom Farrington | |
/video-lectures/mcrpc-treatmen... | Radium-223 in Clinical Practice - Phillip J. Koo | |
/video-lectures/mhspc/video/me... | Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans | |
/video-lectures/upper-tract-ur... | Challenges in the Diagnosis and Treatment of UTUC - Peter Black | |
/video-lectures/imaging-prosta... | Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman | |
/video-lectures/expert-voice/v... | Immunotherapy Across Genitourinary Malignancies - James Gulley | |
/video-lectures/advanced-prost... | Optimizing ADT in Prostate Cancer Patients - Tom Keane | |
/video-lectures/journal-club/v... | Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety | |
/video-lectures/bladder-cancer... | High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks | |
/video-lectures/advanced-kidne... | CARMENA: Practice Changing Strategies for Kidney Cancer | |
/video-lectures/advanced-prost... | Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi | |
/video-lectures/advanced-bladd... | Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg | |
/video-lectures/lower-urinary-... | Nocturia in the Aging Patient, Assessment and Treatment- Susann Varano | |
/video-lectures/advanced-prost... | Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng | |
/video-lectures/crpc-w-bone-me... | The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor | |
/video-lectures/bladder-cancer... | Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas | |
/video-lectures/advanced-prost... | Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov | |
/video-lectures/advanced-prost... | Clinical Implications of the Abi Race Study: Interview with Dan George | |
/video-lectures/crpc-w-bone-me... | Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo | |
/video-lectures/prostate-cance... | Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng | |
/video-lectures/localized-pros... | The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons | |
/video-lectures/prostate-cance... | Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans | |
/video-lectures/advanced-prost... | New Concepts in ADT- Thomas Keane | |
/video-lectures/bladder-cancer... | Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas | |
/video-lectures/nmcrpc/video/m... | nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad. | |
/video-lectures/bladder-health... | Defining Bladder Health - Ariana Smith | |
/video-lectures/bladder-cancer... | A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore | |
/video-lectures/nmcrpc/video/m... | Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain | |
/video-lectures/advanced-prost... | Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin | |
/video-lectures/aua-2025/video... | Treatment Intensification Strategies for High-Risk Prostate Cancer Patients - Aaron Berger | |
/video-lectures/asco-gu-2025/v... | Combining Genomic Classifier and Digital Pathology Artificial Intelligence in Prostate Cancer Risk Stratification - Daniel Spratt | |
/video-lectures/genomic-classi... | Precision Risk Assessment in Prostate Cancer: Growing Utility in NCCN Guidelines - Rashid Sayyid & Zachary Klaassen | |
/video-lectures/genomic-classi... | Textduplikat | Deciphering Prostate Cancer: How Genomic Biomarkers are Shaping Treatment Decisions - Paul Nguyen |
/video-lectures/genomic-classi... | Textduplikat | Correlation and Validation of Gene Expression Classifiers in Prostate Cancer: A Large-Scale Study - Daniel Spratt |
/video-lectures/genomic-classi... | Decipher® Scores and PSMA PET Imaging: A Correlative Study in High-Risk Prostate Cancer - Amar Kishan | |
/video-lectures/genomic-classi... | Integrating the Use of Prostate Genomic Classifiers into Clinical Practice - A Clinical Pathway Approach - Katie Murray and Anne Lizardi-Calvaresi | |
/video-lectures/genomic-classi... | Transcriptome-Based Prognostic and Predictive Biomarker Analysis - The DECIPHER® Genomic Classifier for Prostate Cancer - Ashley Ross | |
/video-lectures/genomic-classi... | Textduplikat | Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard |
/video-lectures/genomic-classi... | The Molecular Biology of Prostate Cancer - Christopher Barbieri | |
/video-lectures/genomic-classi... | Textduplikat | An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abira... |
/video-lectures/genomic-classi... | The Use of the Decipher® Biopsy Test Prior to Prostatectomy - Ashley Ross | |
/video-lectures/genomic-classi... | Textduplikat | High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack |
/video-lectures/immunotherapy-... | Sasanlimab Combined with BCG for High-Risk Non-Muscle Invasive Bladder Cancer - Matthew Galsky | |
/video-lectures/high-risk-non-... | Textduplikat | SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden |
/video-lectures/high-risk-non-... | Novel Therapies for Non-Muscle Invasive Bladder Cancer: Expert Review - Felix Guerrero-Ramos | |
/video-lectures/clinical-trial... | Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore | |
/video-lectures/treatments-in-... | Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram | |
/video-lectures/clinical-trial... | Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore | |
/video-lectures/eau-2025/video... | Complete vs Partial TURBT for Muscle-Invasive Bladder Cancer Treatment - Fredrik Liedberg, Marco Moschini & Benjamin Pradere | |
/video-lectures/eau-2025/video... | Treatment Approaches for Node-Positive Locally Advanced Bladder Cancer - Shilpa Gupta & Felix Guerrero-Ramos | |
/video-lectures/advanced-bladd... | Node-Positive Bladder Cancer: Treatment, Biomarkers, and Surgical Considerations - Neema Navai | |
/video-lectures/advanced-bladd... | Textduplikat | A Case-Based Discussion on First-Line EV + Pembrolizumab for Metastatic Urothelial Carcinoma - Neal Shore |
/video-lectures/asco-gu-2025/v... | NEO-BLAST Trial: Evaluating Bladder Preservation After Neoadjuvant Therapy in Bladder Cancer - Marie-Pier St-Laurent | |
/video-lectures/asco-gu-2025/v... | Circulating Tumor DNA as Prognostic Biomarker in Perioperative Management of Muscle Invasive Bladder Cancer - Nimira Alimohamed | |
/video-lectures/asco-gu-2025/v... | Safety of Combining Radiotherapy with Antibody Drug Conjugates in Advanced Urothelial Carcinoma - Neil Desai | |
/video-lectures/asco-gu-2025/v... | TROPION-PanTumor01 Trial for Advanced Bladder Cancer - Funda Meric-Bernstam | |
/video-lectures/asco-gu-2025/v... | Genomic Characterization of Young-Onset Bladder Cancer - Alina Basnet | |
/video-lectures/asco-gu-2025/v... | Textduplikat | Real-World Safety Profiles of First-Line Therapies for Advanced Urothelial Carcinoma - Amanda Nizam |
/video-lectures/asco-gu-2025/v... | Phase II Trial Results of Disitamab Vedotin and Toripalimab Combination for Muscle-Invasive Bladder Cancer - Xinan Sheng | |
/video-lectures/asco-gu-2025/v... | ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions - Nimira Alimohamed | |
/video-lectures/asco-gu-2025/v... | Avelumab’s Survival Impact in Diabetic vs Non-Diabetic Bladder Cancer Patients - Shilpa Gupta | |
/video-lectures/asco-gu-2025/v... | Textduplikat | Adjuvant Nivolumab in High-Risk Muscle Invasive Bladder Cancer Analysis Shows Improved Outcomes for Patients: CheckMate 274 - Matthew Galsky |
/video-lectures/asco-gu-2025/v... | RETAIN-2 Study Shows Promise for Bladder Cancer Preservation - Pooja Ghatalia | |
/video-lectures/asco-gu-2025/v... | The NIAGARA Trial Highlights the Role of Durvalumab in Bladder Cancer Treatment - Matthew Galsky | |
/video-lectures/asco-gu-2025/v... | Enfortumab Vedotin and Pembrolizumab Demonstrate Durable Responses in Advanced Bladder Cancer - Thomas Powles | |
/video-lectures/advanced-bladd... | Enfortumab Vedotin and Pembrolizumab in Practice: A Case Study in Metastatic Urothelial Carcinoma - Brenda Martone | |
/video-lectures/advanced-bladd... | Adaptive Radiotherapy in Bladder Cancer: Phase II Results from the RAIDER II Trial - Robert Huddart | |
/video-lectures/advanced-bladd... | RETAIN Trial: Sparing Bladder Removal in Muscle-Invasive Bladder Cancer Patients - Daniel Geynisman | |
/video-lectures/suo-2024/video... | Adjuvant Systemic Therapies for Urothelial Carcinoma: Current Evidence and Future Directions - Jean Hoffman-Censits | |
/video-lectures/suo-2024/video... | Serial ctDNA Testing Identifies Bladder Cancer Patients Who May Avoid Adjuvant Therapy - Joaquim Bellmunt | |
/video-lectures/suo-2024/video... | Consolidative Local Therapy in Metastatic Bladder Cancer After Systemic Treatment Response - Fed Ghali | |
/video-lectures/suo-2024/video... | Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer - Jacqueline Brown | |
/video-lectures/advanced-bladd... | Real-World Effectiveness of Enfortumab Vedotin in Advanced Urothelial Carcinoma - Umang Swami | |
/video-lectures/esmo-2024/vide... | Futibatinib and Pembrolizumab in FGFR-Altered Urothelial Cancer - Vadim Koshkin | |
/video-lectures/suo-2024/video... | Advances in Muscle-Invasive Bladder Cancer: Systemic Therapies and Surgical Innovations - Jen-Jane Liu | |
/video-lectures/bcan-think-tan... | Lessons Learned from Other Cancers that Can be Applied to Bladder Cancer - Petros Grivas | |
/video-lectures/suo-2024/video... | Textduplikat | Emerging Neoadjuvant Combinations for Muscle-Invasive Bladder Cancer - Mamta Parikh |
/video-lectures/suo-2024/video... | Textduplikat | BCG Unresponsive Bladder Cancer in 2024 - Ashish Kamat |
/video-lectures/advanced-bladd... | Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract | |
/video-lectures/lugpa-2024/vid... | Five Things Urologists Need to Know About Bladder and Kidney Cancer in 2025 "Presentation" - Gautam Jayram | |
/video-lectures/advanced-bladd... | Study Finds Whole Pelvis Radiotherapy Superior to Bladder-Only in MIBC Treatment - Gautier Marcq | |
/video-lectures/esmo-2024/vide... | Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg | |
/video-lectures/advanced-bladd... | Quality of life after Trimodality Therapy - Kimberley Mak | |
/video-lectures/esmo-2024/vide... | Textduplikat | 5-Year Survival Outcomes in Cisplatin-Ineligible Patients from EV-103 - Jonathan Rosenberg |
/video-lectures/esmo-2024/vide... | NIAGARA Trial Shows Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles | |
/video-lectures/esmo-2024/vide... | Textduplikat | Nectin-4 Expression Not Predictive of Response in Enfortumab Vedotin Therapy - Thomas Powles |
/video-lectures/bladder-cancer... | Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka | |
/video-lectures/bcan-think-tan... | Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global Implementation - Andrea Apolo | |
/video-lectures/advanced-bladd... | Textduplikat | SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner |
/video-lectures/esmo-2024/vide... | EV-302 Trial Analysis Evaluating Nectin-4 in Urothelial Cancer - Thomas Powles | |
/video-lectures/esmo-2024/vide... | Textduplikat | NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles |
/video-lectures/bladder-cancer... | Variant Histology Bladder Cancer Challenges and Future Directions - Syed Hussain | |
/video-lectures/bcan-think-tan... | Bladder Cancer Research Explores Fecal Transplants and Nutritional Strategies - Laura Bukavina | |
/video-lectures/esmo-2024/vide... | Highlights in Non-Prostate GU Oncology from ESMO 2024 - Ignacio Duran | |
/video-lectures/esmo-2024/vide... | Enfortumab Vedotin and Stereotactic Radiation Tested Before Surgery in Muscle-Invasive Bladder Cancer in STAR-EV Trial - Tian Zhang | |
/video-lectures/esmo-2024/vide... | Event-Free Survival as Surrogate Endpoint in Muscle Invasive Bladder Cancer Research - Cora Sternberg | |
/video-lectures/esmo-2024/vide... | Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis | |
/video-lectures/esmo-2024/vide... | Textduplikat | SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi |
/video-lectures/esmo-2024/vide... | Textduplikat | Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky |
/video-lectures/esmo-2024/vide... | Textduplikat | AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer - Andrea Apolo |
/video-lectures/advanced-bladd... | Textduplikat | EV-302 Trial Establishes Treatment Standard for Urothelial Carcinoma - Daniel Petrylak |
/video-lectures/bladder-cancer... | Textduplikat | Trimodal Therapy in Urothelial vs Non-Urothelial Bladder Cancer - Mario de Angelis |
/video-lectures/asco-2024/vide... | The Best of ASCO 2024 in Advanced Bladder Cancer - Shilpa Gupta | |
/video-lectures/asco-2024/vide... | Small Cell Neuroendocrine Carcinoma of Urinary Tract: Relapse Factors & Treatment - Omar Alhalabi | |
/video-lectures/bladder-cancer... | Textduplikat | dMMR and MSI-H in Urothelial Carcinoma: Prevalence and Treatment Implications - Elias Chandran |
/video-lectures/bladder-cancer... | Textduplikat | Bladder-Sparing Chemoradiation for Localized Bladder Cancer: Addressing the Unmet Need - Brent Rose |
/video-lectures/asco-2024/vide... | EV-302 Subgroup Analysis: Improved Outcomes for Cisplatin-Ineligible Advanced Urothelial Cancer Patients - Michiel Van der Heijden | |
/video-lectures/advanced-bladd... | SunRISe-2 Trial: TAR-200 and Cetrelimab vs. Chemoradiotherapy for Muscle-Invasive Bladder Cancer - Stephen Williams | |
/video-lectures/advanced-bladd... | Textduplikat | Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions - Matthew Galsky & Neal Shore |
/video-lectures/non-muscle-inv... | Textduplikat | Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie |
/video-lectures/aua-2024/video... | AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser | |
/video-lectures/advanced-bladd... | Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial - Neal Shore | |
/video-lectures/clinical-trial... | Textduplikat | Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore |
/video-lectures/bladder-cancer... | Textduplikat | Balancing Bladder Preservation with Effective Treatment in Cancer Care - Petros Grivas |
/video-lectures/ibcg-aua-2024-... | Textduplikat | Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla |
/video-lectures/advanced-bladd... | Stool Microbiome Signature Predicts Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - Filippo Pederzoli & Massimo Alfano | |
/video-lectures/advanced-bladd... | EV-302 Subgroup Analyses: Enfortumab Vedotin + Pembrolizumab Effective Across Patient Subsets in Metastatic Urothelial Cancer - Jonathan Rosenberg | |
/video-lectures/eau-2024/video... | Textduplikat | Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians - Cora Sternberg |
/video-lectures/advanced-bladd... | Textduplikat | Preclinical Study Evaluates Enfortumab Vedotin and Sacituzumab Govitecan with Radiation for Bladder Cancer - Kent Mouw |
/video-lectures/advanced-bladd... | Textduplikat | Genomic Tumor Correlates of Response to Trimodal Therapy for Muscle-Invasive Bladder Cancer - Sophia Kamran |
/video-lectures/journal-club/v... | Textduplikat | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen |
/video-lectures/advanced-bladd... | Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma - Arlene Siefker-Radtke | |
/video-lectures/asco-gu-2024/v... | EV-302: Enfortumab Vedotin + Pembrolizumab Outperforms Chemo in Untreated Advanced Urothelial Cancer - Michiel Simon Van der Heijden | |
/video-lectures/asco-gu-2024/v... | Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings - Andrea Apolo | |
/video-lectures/asco-gu-2024/v... | Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer - Amanda Nizam | |
/video-lectures/asco-gu-2024/v... | Combination Maintenance Therapy for Advanced Bladder Cancer Explored in MAIN-CAV Study - Shilpa Gupta | |
/video-lectures/health-policy-... | Utilization of Neoadjuvant Chemo Before Cystectomy - Hiten Patel | |
/video-lectures/advanced-bladd... | International Panel Defines Endpoints and Control Arms for Trials in Locally Advanced and Metastatic Bladder Cancer, Journal Club - Rashid Sayyid & Zachary K... | |
/video-lectures/advanced-bladd... | Multi-Disciplinary Panel Defines Clinical Trial Framework for Muscle-Invasive Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen | |
/video-lectures/esmo-2023/vide... | Gemcitabine, Cisplatin and Immunotherapy: A Promising Mix for Advanced Bladder Cancer - Guru Sonpavde & Matthew Galsky | |
/video-lectures/esmo-2023/vide... | Novel Antibody-Drug Conjugate Combination Yields High Response in Advanced Bladder Cancer - Guru Sonpavde & Bradley McGregor | |
/video-lectures/esmo-2023/vide... | For Bladder Cancer Patients, New Hope From Immunotherapy Innovations from ESMO 2023 - Petros Grivas | |
/video-lectures/esmo-2023/vide... | The EV-302 Study and the Implications for Metastatic Bladder Cancer Care - Cora Sternberg | |
/video-lectures/asco-2023/vide... | EV-103 Study Update: Impressive Four-Year Data on Enfortumab Vedotin and Pembrolizumab Combination in Urothelial Cancer - Shilpa Gupta | |
/video-lectures/asco-2023/vide... | Outcomes with Immune Checkpoint Inhibitors in Patients with MTAP Alterations in Advanced Urothelial Carcinoma - Rafee Talukder | |
/video-lectures/asco-2023/vide... | Textduplikat | A Breakthrough in Urothelial Cancer Treatment: Enfortumab Vedotin Combination Therapy - Expert Insights and Impressive Response Rates - Jonathan E. Rosenberg |
/video-lectures/advanced-bladd... | Textduplikat | Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jaso... |
/video-lectures/advanced-bladd... | New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with Second-Line Immune Checkpoint Inhibitors - Beyond the Abstract | |
/video-lectures/san-raffaele-u... | The San Raffaele Urologic Oncology Retreat: Examples of ECOG-ACRIN Research Initiatives - Petros Grivas | |
/video-lectures/aua-2023/video... | The TAR-200 Device in Muscle-Invasive Bladder Cancer: Safety, Efficacy, and Future Prospects - Mark D. Tyson, II | |
/video-lectures/aua-2023/video... | Addressing Challenges in Bladder Cancer Surgery: Enhancing Patient Outcomes and Preparing for Recovery - Sarah Psutka | |
/video-lectures/aua-2023/video... | Full Data Analysis of the Biology and Performance of Pre- and Post-Pembrolizumab VI-RADS for Predicting Pathological Response in MIBC: Insights from a Compre... | |
/video-lectures/bladder-cancer... | Pros and Cons of Organ-Sparing Cystectomy in Bladder Cancer Patients: Balancing Oncologic and Functional Outcomes - Param Mariappan & Maria Carmen Mir | |
/video-lectures/asco-gu-2023/v... | Long-Term Results of the IMvigor130 Study: Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer – Matthew Galsky | |
/video-lectures/asco-gu-2023/v... | Neoadjuvant Chemo-Immunotherapy Affect on Downstaging in Cisplatin-Eligible and Ineligible MIBC Patients Prior to Definitive Surgery, HCRN GU14-188: Phase Ib... | |
/video-lectures/asco-gu-2023/v... | Gemcitabine, Cisplatin, and Nivolumab with Selective Bladder Sparing in MIBC: Co-Primary Endpoint Analysis of HCRN GU 16-256 Phase II Trial - Matthew Galsky | |
/video-lectures/asco-gu-2023/v... | Exploring Genetic Biomarkers of Response to Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of UNITE Dataset - Tanya Jindal & Vadim Koshkin | |
/video-lectures/asco-gu-2023/v... | Assessing the Impact of Enfortumab Vedotin and Pembrolizumab on QoL and Symptom Management in Urothelial Carcinoma: EV-103 Cohort K Study Results - Matthew M... | |
/video-lectures/asco-gu-2023/v... | The Phase 1B NABUCCO Trial: The Use of Either High or Low-Dose Preoperative Ipilimumab plus Nivolumab in Patients with Stage III Urothelial Cancer – Michiel ... | |
/video-lectures/asco-gu-2023/v... | Extended Follow-Up Results of the CheckMate 274 Trial: Adjuvant Nivolumab for Resected Muscle-Invasive Urothelial Carcinoma - Matthew Galsky | |
/video-lectures/asco-gu-2023/v... | Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar | |
/video-lectures/advanced-bladd... | The Association Between FGFR3 Alterations and Response to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma - Gopa Iyer | |
/video-lectures/esmo-2022/vide... | The Use of Biomarkers in the Adjuvant Setting to Understand the Effect of Nivolumab in the Checkmate 274 Study - Andrea Necchi | |
/video-lectures/asco-gu-2023/v... | Results from the Phase 1b/2 FIDES-02 Study: Derazantinib for Metastatic Bladder Cancer with Activating FGFR1/2/3 Genetic Aberrations - Andrea Necchi | |
/video-lectures/asco-gu-2023/v... | Extended Follow-Up Results CheckMate 274 Trial and Results of Pembrolizumab Monotherapy in BCG-Unresponsive HR NMIBC: Findings from Cohort B of the KEYNOTE-0... | |
/video-lectures/asco-gu-2023/v... | TROPHY-U-01 Cohort 3 Primary Analysis Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer That Progressed a... | |
/video-lectures/asco-gu-2023/v... | The Future of Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Urothelial Carcinoma - Andrea Apolo | |
/video-lectures/advanced-bladd... | The Role of Avelumab Switch Maintenance Immunotherapy in the Front-Line Space of Patients with Advanced Urothelial Cancer - Srikala Sridhar | |
/video-lectures/advanced-bladd... | From Dismal to Promising: Discoveries Transforming Treatment Options for Advanced Urothelial Carcinoma - Shilpa Gupta | |
/video-lectures/esmo-2022/vide... | Results of Cohort K of the EV-103 Trial EV Monotherapy or in Combination With Pembro in Previously Untreated Cisplatin-Ineligible Patients With Locally Advan... | |
/video-lectures/asco-2022/vide... | Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg | |
/video-lectures/journal-club/v... | EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma, Journal Club - Christopher Wall... | |
/video-lectures/esmo-2022/vide... | Textduplikat | EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advan... |
/video-lectures/journal-club/v... | Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen | |
/video-lectures/journal-club/v... | Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Cl... | |
/video-lectures/journal-club/v... | CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Cl... | |
/video-lectures/ibcg-aua-2024-... | Textduplikat | The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefke... |
/video-lectures/asco-2022/vide... | ATLANTIS Trial Explores Precision Medicine in Urothelial Carcinoma - Robert Jones | |
/video-lectures/asco-gu-2022/v... | Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis | |
/video-lectures/advanced-bladd... | Textduplikat | Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukd... |
/video-lectures/advanced-bladd... | Navigating the Complex Landscape of Adjuvant Trials in Urothelial Carcinoma - Robert Dreicer | |
/video-lectures/advanced-bladd... | The Role of ctDNA in Metastatic Urothelial Cancer - Alexander Wyatt | |
/video-lectures/asco-gu-2022/v... | Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa | |
/video-lectures/asco-gu-2022/v... | Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb | |
/video-lectures/advanced-bladd... | Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye | |
/video-lectures/asco-gu-2022/v... | Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian | |
/video-lectures/asco-gu-2022/v... | The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose | |
/video-lectures/asco-gu-2022/v... | The Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in the Treatment of Cisplatin-Ineligible Patients in Advanced Urothelial Carcinoma (L... | |
/video-lectures/asco-gu-2022/v... | Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde | |
/video-lectures/asco-gu-2022/v... | Sacituzumab Govitecan in Combination with Pembrolizumab in Metastatic Urothelial Cancer - Petros Grivas | |
/video-lectures/advanced-bladd... | Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis | |
/video-lectures/advanced-bladd... | Textduplikat | Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack |
/video-lectures/lugpa-2024/vid... | Biomarkers and Next Generation Sequencing in Advanced Bladder Cancer - Noah Hahn | |
/video-lectures/advanced-bladd... | Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew... | |
/video-lectures/advanced-bladd... | Textduplikat | Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo |
/video-lectures/journal-club/v... | Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 ... | |
/video-lectures/asco-2021/vide... | Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt | |
/video-lectures/asco-2021/vide... | Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial ... | |
/video-lectures/advanced-bladd... | Beyond Clinical Trials: Real-World Success with Trimodality Therapy in Bladder Cancer - Sean Sachdev & Praneet Polineni | |
/video-lectures/asco-2021/vide... | Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatme... | |
/video-lectures/advanced-bladd... | Advances in the Treatment of Metastatic Urothelial Cancer - Matthew Galsky | |
/video-lectures/advanced-bladd... | Breaking Down the TROPHY-U-01 Trial: How Sacituzumab Govitecan Earned FDA Approval for Advanced Bladder Cancer - Neeraj Agarwal & Petros Grivas | |
/video-lectures/advanced-bladd... | Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and Ewan Gibb | |
/video-lectures/advanced-bladd... | The Role of Imaging in Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: A Case Study of PURE-01 - Andrea Necchi & Laura Marandino | |
/video-lectures/advanced-bladd... | TROPHY-U-01 Results Lead to Accelerated Approval of Sacituzumab Govitecan (Trodelvy) for Pretreated Metastatic Urothelial Carcinoma - Scott Tagawa | |
/video-lectures/clinical-trial... | Chemoradiation in Urothelial Carcinoma: The Herculean Effort Behind the SWOG 1806 Trial - Petros Grivas | |
/video-lectures/clinical-trial... | Variant Histologies of Bladder Cancer - Petros Grivas | |
/video-lectures/advanced-bladd... | Textduplikat | Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal |
/video-lectures/advanced-bladd... | Voluntary Withdrawal In The US of Durvalumab and of Atezolizumab in Metastatic Urothelial Carcinoma - Petros Grivas | |
/video-lectures/advanced-bladd... | Operationalizing the Use of Avelumab in Clinical Practice, The Phase III JAVELIN Bladder 100 Trial - Brenda Martone | |
/video-lectures/advanced-bladd... | Characterization of The Genomic Landscape of Post-Neoadjuvant Chemotherapy in MIBC Patients- Andrew Lenis | |
/video-lectures/advanced-bladd... | Metastatic and Muscle-Invasive Bladder Cancer European Association of Urology (EAU) Guidelines - J. Alfred Witjes | |
/video-lectures/advanced-bladd... | Molecular Changes Associated with Treatment Response in Muscle-Invasive Bladder Cancer Patients Treated with Cisplatin-Based Chemotherapy - Lars Dyrskjøt | |
/video-lectures/advanced-bladd... | Two-year JAVELIN Solid Tumor Data Phase 1 Final Results - Andrea Apolo | |
/video-lectures/advanced-bladd... | Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar | |
/video-lectures/advanced-bladd... | Textduplikat | Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III |
/video-lectures/advanced-bladd... | Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden | |
/video-lectures/advanced-bladd... | Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde | |
/video-lectures/advanced-bladd... | Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar | |
/video-lectures/advanced-bladd... | ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas | |
/video-lectures/advanced-bladd... | ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks | |
/video-lectures/advanced-bladd... | Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta | |
/video-lectures/advanced-bladd... | Textduplikat | The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo |
/video-lectures/advanced-bladd... | Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas | |
/video-lectures/advanced-bladd... | Treatment Approach: Case Study in Aggressiveness Metastatic Urothelial Carcinoma - Makarand Khochikar | |
/video-lectures/advanced-bladd... | Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas | |
/video-lectures/advanced-bladd... | Textduplikat | JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer ... |
/video-lectures/advanced-bladd... | Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Carcinoma - Ali Khaki | |
/video-lectures/advanced-bladd... | Progress in Bladder Cancer Research - Bishoy Faltas | |
/video-lectures/advanced-bladd... | IMvigor010 Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma -... | |
/video-lectures/advanced-bladd... | JAVELIN Bladder 100: Avelumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma - Thomas Powles | |
/video-lectures/advanced-bladd... | Controversial and Complex Cases in Urothelial Cancer - Srikala Sridhar | |
/video-lectures/advanced-bladd... | The Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in MIBC - Andrea Necchi | |
/video-lectures/advanced-bladd... | The Landscape of Advanced Bladder Cancer: A Review of the Last 30-Years - Cora Sternberg | |
/video-lectures/advanced-bladd... | Enfortumab Vedotin for Advanced Urothelial Carcinoma - Jonathan Rosenberg | |
/video-lectures/advanced-bladd... | Updates on Bladder Cancer Clinical Trials ASCO GU 2020 - Matthew Galsky | |
/video-lectures/advanced-bladd... | Recent Advances in the Treatment of Metastatic Urothelial Cancer - Petros Grivas | |
/video-lectures/advanced-bladd... | Treatments in Development for Muscle-invasive Bladder Cancer - Min Yuen Teo | |
/video-lectures/advanced-bladd... | Advanced Bladder Cancer Clinic: Are you Ready? - Neal Shore | |
/video-lectures/advanced-bladd... | Immunotherapy and Chemotherapy Use in Patients with Metastatic Bladder Cancer - Ronac Mamtani and Ravi Parikh | |
/video-lectures/advanced-bladd... | Circulating Tumor DNA in Urothelial Cancer - Interview with Bishoy Faltas | |
/video-lectures/advanced-bladd... | Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas | |
/video-lectures/advanced-bladd... | Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky | |
/video-lectures/advanced-bladd... | Antibody Drug Conjugates for the Treatment of Metastatic Urothelial Carcinoma - Petros Grivas | |
/video-lectures/advanced-bladd... | Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas | |
/video-lectures/advanced-bladd... | Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas | |
/video-lectures/advanced-bladd... | The Performance Status and Response to Immune Checkpoint Inhibition in Patients with Advanced Urothelial Carcinoma - Ali Khaki | |
/video-lectures/advanced-bladd... | Results from CALGB 90601 in Metastatic Urothelial Carcinoma - Jonathan Rosenberg | |
/video-lectures/advanced-bladd... | Novel New Approaches in the Neoadjuvant Disease Setting for Bladder Cancer - Petros Grivas | |
/video-lectures/advanced-bladd... | Urinary Diversion after Radical Cystectomy - Morgan Roupret | |
/video-lectures/advanced-bladd... | Assessing and Managing Toxicities with Immune Checkpoint Inhibitors - Brenda Martone | |
/video-lectures/advanced-bladd... | Erdafitinib in Bladder Cancer - Arjun Balar | |
/video-lectures/advanced-bladd... | Implications of Clinical Response Following Neoadjuvant Chemotherapy - Seth Lerner | |
/video-lectures/advanced-bladd... | Treating Advanced Bladder Cancer - Petros Grivas | |
/video-lectures/advanced-bladd... | Optimizing Treatment Outcomes in Muscle Invasive Bladder Cancer (MIBC) - Wassim Kassouf | |
/video-lectures/advanced-bladd... | Bladder Sparing Strategies for Urothelial Cancer - Jason Efstathiou | |
/video-lectures/advanced-bladd... | Neoadjuvant Treatment in Muscle Invasive Bladder Cancer- Andrea Necchi | |
/video-lectures/advanced-bladd... | Antibody-drug Conjugate (ADC) Sacituzumab Govitecan in Metastatic UroThelial Carcinoma - Scott Tagawa | |
/video-lectures/advanced-bladd... | Joshua J. Meeks on SWOG 1806 Study | |
/video-lectures/advanced-bladd... | Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer - Matthew Galsky | |
/video-lectures/advanced-bladd... | Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo | |
/video-lectures/advanced-bladd... | A Conversation on Immuno-Oncology in Bladder Cancer - Petros Grivas | |
/video-lectures/advanced-bladd... | Update on Immunotherapy Advances in Renal and Bladder Cancer - Cora Sternberg | |
/video-lectures/advanced-bladd... | Advances in Bladder Cancer Beyond Immunotherapy and Checkpoint Inhibitors - Evan Yu | |
/video-lectures/advanced-bladd... | Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials -Pedro Barata | |
/video-lectures/advanced-bladd... | Textduplikat | Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg |
/video-lectures/advanced-bladd... | The State of Advanced Bladder Cancer - New Data from AACR 2018 - Interview with Arjun Balar | |
/video-lectures/integrating-17... | Integration of Lutetium-177 and the Value of Shared Decisions with Practice Stakeholders - Jeffrey Zemencik | |
/video-lectures/integrating-17... | Expanding the Nuclear Hot Lab to Accommodate Lutetium-177 - Lyanne Gomez | |
/video-lectures/integrating-17... | Finding the Right Patient for Lutetium-177 PSMA Treatment - Kara Cossis | |
/video-lectures/integrating-17... | Coordinating & Transitioning Patient Care for Patients Who Receive Lutetium-177 - Elizabeth Davis | |
/video-lectures/integrating-17... | A Urologist’s Multidisciplinary Approach to Clinical Management of the Patient Receiving Lutetium-177 - Benjamin Lowentritt | |
/video-lectures/integrating-17... | Radiation Safety Considerations for the Authorized User when Operationalizing Lutetium-177 in the Urology Clinic - Robert Brookland | |
/video-lectures/integrating-17... | Multidisciplinary Transitions in Care for Patients Receiving Lutetium-177 - Benjamin Lowentritt & Robert Brookland | |
/video-lectures/beyond-androge... | AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg | |
/video-lectures/beyond-androge... | Textduplikat | Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming |
/video-lectures/beyond-androge... | Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay | |
/video-lectures/beyond-androge... | Bone Health Management for Advanced Prostate Cancer - Fred Saad | |
/video-lectures/beyond-androge... | Tumor Heterogeneity Selective Pressure – Why We Need New Targets? - Oliver Sartor | |
/video-lectures/beyond-androge... | Unlocking Precision Care: Germline & Somatic Literacy in Prostate Cancer - Elisabeth Heath | |
/video-lectures/beyond-androge... | Textduplikat | Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi |
/video-lectures/beyond-androge... | PARP Inhibitors: Targeting DNA Repair Pathways - Neal Shore | |
/video-lectures/beyond-androge... | The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical Need for New Targets and Novel Treatment Pathways - Dan George | |
/video-lectures/beyond-androge... | The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay | |
/video-lectures/beyond-androge... | The Current Treatment Landscape in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong | |
/video-lectures/beyond-androge... | PSMA PET as a Biomarker for Advanced Prostate Cancer - Oliver Sartor | |
/video-lectures/beyond-androge... | 2023 Key Learnings in mCRPC Treatments – Alicia Morgans | |
/video-lectures/beyond-androge... | Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options? - Brenda Ma... | |
/video-lectures/beyond-androge... | Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? - Brenda Martone | |
/video-lectures/beyond-androge... | Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer | |
/video-lectures/imaging-prosta... | Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman | |
/video-lectures/apccc-2024/vid... | Hypofractionation in Prostate Cancer Radiotherapy: Balancing Efficacy and Safety - Neha Vapiwala | |
/video-lectures/apccc-2024/vid... | Textduplikat | Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin |
/video-lectures/localized-pros... | Textduplikat | Testosterone Recovery After ADT: Timing, Predictive Factors, and Clinical Implications - Pierre Blanchard |
/video-lectures/apccc-2024/vid... | Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas | |
/video-lectures/apccc-2024/vid... | EMBARK Trial: Enzalutamide Monotherapy and Combination Therapy for High-Risk Biochemical Recurrence - Neal Shore | |
/video-lectures/advanced-prost... | Textduplikat | Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt |
/video-lectures/apccc-2024/vid... | Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith | |
/video-lectures/psma-targetedt... | Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett | |
/video-lectures/mhspc/video/me... | Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis | |
/video-lectures/apccc-2024/vid... | Textduplikat | Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis |
/video-lectures/apccc-2024/vid... | Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging - Oliver Sartor | |
/video-lectures/mhspc/video/me... | Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris | |
/video-lectures/apccc-2024/vid... | Textduplikat | The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo |
/video-lectures/apccc-2024/vid... | Bone Health in Advanced Prostate Cancer: Findings from the STAMPEDE Trial and Hospital Episode Statistics - Noel Clarke | |
/video-lectures/apccc-2024/vid... | APCCC 2024: Bridging Clinical Gaps in Prostate Cancer Care - Silke Gillessen | |
/video-lectures/apccc-2024/vid... | Highlighting APCCC 2024: An International Prostate Cancer Meeting - Silke Gillessen & Aurelius Omlin | |
/video-lectures/apccc-2024/vid... | Navigating the Future of Prostate Cancer Treatment and Global Access at APCCC 2024 - Silke Gillessen | |
/video-lectures/apccc-2024/vid... | PSMA PET Imaging Hot Topics - Neal Shore & Jason Efstathiou | |
/video-lectures/apccc-2024/vid... | Textduplikat | A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore |
/video-lectures/apccc-2024/vid... | Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer - Neal Shore | |
/video-lectures/apccc-2024/vid... | Textduplikat | APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu |
/video-lectures/apccc-2024/vid... | Textduplikat | Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans |
/video-lectures/apccc-2024/vid... | Immune Checkpoint B7-H3 - APCCC 2022 - Emmanuel Antonarakis | |
/video-lectures/apccc-2024/vid... | Optimal Sequencing - Should It Include Radium Given Lutetium? - Joe O'Sullivan | |
/video-lectures/apccc-2024/vid... | Genomic and Clinical Markers in nmCRPC APCCC 2022 Presentation - Joaquin Mateo | |
/video-lectures/apccc-2024/vid... | From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi | |
/video-lectures/apccc-2024/vid... | Emerging Therapies and Therapeutic Targets in Prostate Cancer - Mark Rubin | |
/video-lectures/apccc-2024/vid... | Ironman Registry: Pioneering Data Collection and Biomarker Analysis in Prostate Cancer Research Daniel George | |
/video-lectures/apccc-2024/vid... | How Can Treatment Be Individualized By Using Genomic Classifiers? APCCC 2022 Presentation - Felix Feng | |
/video-lectures/apccc-2024/vid... | Who Needs Early Salvage Radiotherapy and Who Needs Adjuvant Radiotherapy in 2022? - Kosj Yamoah | |
/video-lectures/apccc-2024/vid... | Incorporating Molecular Testing into Clinical Practice for Prostate Cancer - Elena Castro & Colin Pritchard | |
/video-lectures/apccc-2024/vid... | Textduplikat | Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan |
/video-lectures/apccc-2024/vid... | De-escalation Treatment Strategies in Metastatic Hormone-Sensitive Prostate Cancer - Bertrand Tombal | |
/video-lectures/apccc-2024/vid... | When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Karim Fizazi | |
/video-lectures/apccc-2024/vid... | The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo | |
/video-lectures/apccc-2024/vid... | Textduplikat | PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad |
/video-lectures/apccc-2024/vid... | Closing Remarks from the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) - Silke Gillessen, Aurelius Omlin, Neal Shore, Charles Ryan & Alicia... | |
/video-lectures/apccc-2024/vid... | Systemic Treatment in the Context of Salvage Radiation and Biochemical Recurrence - Piet Ost | |
/video-lectures/genomic-classi... | The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal | |
/video-lectures/apccc-2024/vid... | Demystifying PSMA Theranostics: A Discussion on Implementing Lutetium-177 Treatment - Oliver Sartor | |
/video-lectures/apccc-2024/vid... | Beyond Clinical Trials: Mastering Patient Care for Lutetium-PSMA-617 Therapy - Michael Morris | |
/video-lectures/apccc-2024/vid... | Looking Forward to the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 - Aurelius Omlin | |
/video-lectures/apccc-2024/vid... | Textduplikat | The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen |
/video-lectures/apccc-2024/vid... | The APCCC 2021 Focuses on Key Areas of Advanced Prostate Cancer Management: Newly Diagnosed mHSPC, PSMA in Diagnostics and Therapy and Novel Targets in mCRPC... | |
/video-lectures/apccc-2024/vid... | Looking Forward to The Advanced Prostate Cancer Consensus Conference (APCCC) 2021 - Silke Gillessen and Aurelius Omlin | |
/video-lectures/apccc-2024/vid... | Reflections on Advanced Prostate Cancer Consensus Conference 2019 - Srikala Sridhar | |
/video-lectures/apccc-2024/vid... | The Side Effects of Advanced Prostate Cancer Consensus Conference 2019 (APCCC) - Silke Gillessen and Aurelius Omlin | |
/video-lectures/aua-2025/video... | Textduplikat | Real-World Data Improves NMIBC Risk Assessment with Blue Light Technology - Siamak Daneshmand & Boris Gershman |
/video-lectures/aua-2025/video... | Textduplikat | Platform Reduces Unnecessary Cystoscopies for Hematuria Patients - John Sfakianos |
/video-lectures/non-muscle-inv... | Recombinant BCG Access Program Addresses US Bladder Cancer Shortage - Neal Shore | |
/video-lectures/immunotherapy-... | Textduplikat | Sasanlimab Combined with BCG for High-Risk Non-Muscle Invasive Bladder Cancer - Matthew Galsky |
/video-lectures/aua-2025/video... | Textduplikat | ARANOTE Study Shows Benefits of Deep PSA Response with Darolutamide - Neal Shore |
/video-lectures/aua-2025/video... | Cost-Effectiveness of 89Zr-DFO-Girentuximab PET Scan for Small Renal Mass Diagnosis - Pratik Kanabur | |
/video-lectures/asco-gu-2025/v... | Nadofaragene Firadenovec for BCG-Unresponsive Bladder Cancer: Efficacy, Logistics, and Real-World Implementation - Fed Ghali | |
/video-lectures/non-muscle-inv... | Papillary Non-Muscle Invasive Bladder Cancer Treatment Guidelines Gap - Patrick Soon-Shiong | |
/video-lectures/mcrpc-treatmen... | Health-Related Quality Outcomes for Pre-Chemotherapy mCRPC Treatment - Neal Shore | |
/video-lectures/mhspc/video/me... | Evolution of Treatment Approaches for Metastatic Hormone-Sensitive Prostate Cancer - Pedro Barata | |
/video-lectures/aua-2025/video... | Recombinant BCG Addressing Bladder Cancer Treatment Shortages - Patrick Soon-Shiong | |
/video-lectures/aua-2025/video... | CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder Cancer - Trinity Bivalacqua | |
/video-lectures/mhspc/video/me... | Optimizing Multidisciplinary Care for Metastatic Hormone-Sensitive Prostate Cancer - Zachary Klaassen | |
/actionable-clinical-data/adst... | Reducing Treatment Burden in BCG-Unresponsive NMIBC: A Patient-Centered Approach - Sarah Psutka | |
/actionable-clinical-data/adst... | Real-World Experience With Nadofaragene Firadenovec Treatment for BCG-Unresponsive Bladder Cancer - Mark Tyson & Max Kates | |
/video-lectures/treatments-in-... | Cretostimogene Grenadenorepvec Investigated for BCG-Exposed High-Risk Bladder Cancer in CORE-008 - Trinity Bivalacqua | |
/video-lectures/aua-2025/video... | Management Strategies for Low-Grade Intermediate-Risk Bladder Cancer - Sarah Psutka | |
/video-lectures/aua-2025/video... | BOND-003 Cohort P Results for BCG-Unresponsive Papillary Bladder Tumors - Mark Tyson | |
/video-lectures/aua-2025/video... | CORE-008 Trial Explores Cretostimogene Grenadenorepvec for Multiple Bladder Cancer Patient Groups - Trinity Bivalacqua | |
/video-lectures/aua-2025/video... | Textduplikat | Treatment Intensification Strategies for High-Risk Prostate Cancer Patients - Aaron Berger |
/video-lectures/treatments-in-... | BOND-003 Cohort C Trial Results for Cretostimogene Grenadenorepvec in BCG-Unresponsive Bladder Cancer - Mark Tyson | |
/video-lectures/embark-trial/v... | Textduplikat | EMBARK Trial: Treatment Options for High-Risk Biochemical Recurrence - Neal Shore |
/video-lectures/embark-trial/v... | Comparing EMBARK vs EAU High-Risk Biochemical Recurrence Criteria in Prostate Cancer - Ugo Falagario | |
/video-lectures/asco-gu-2025/v... | EMBARK Trial Subanalysis for High-Risk Biochemical Recurrent Prostate Cancer - Stephen Freedland | |
/video-lectures/esmo-2024/vide... | Textduplikat | EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore |
/video-lectures/embark-trial/v... | Discussion Between Expert Clinicians and Patients on the EMBARK Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg | |
/video-lectures/embark-trial/v... | EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay | |
/video-lectures/apccc-2024/vid... | Textduplikat | EMBARK Trial: Enzalutamide Monotherapy and Combination Therapy for High-Risk Biochemical Recurrence - Neal Shore |
/video-lectures/embark-trial/v... | Textduplikat | The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore |
/video-lectures/embark-trial/v... | Advancing Prostate Cancer Care: The EMBARK Study and Implications for Clinical Practice - Stephen Freedland | |
/video-lectures/prostate-cance... | Novel Hormone Therapy and Coordination of Care in High-Risk Biochemically Recurrent Prostate Cancer - Beyond the Abstract | |
/video-lectures/embark-trial/v... | Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg | |
/video-lectures/embark-trial/v... | Interpreting EMBARK Trial Results: Intensified Treatment and Hormone Therapy in High-Risk Patients - Christian Gratzke | |
/video-lectures/embark-trial/v... | EMBARK Trial Shows Promising Results for High-Risk Prostate Cancer Treatment, Enzalutamide's Impact on Metastasis-Free Survival - Neal Shore | |
/video-lectures/embark-trial/v... | Textduplikat | The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prosta... |
/conference-highlights/aua-202... | Kein Text | |
/conference-highlights/aua-202... | AUA 2025: A Novel Core Needle Biopsy Instrument Designed for Targeted Biopsy | |
/conference-highlights/aua-202... | New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Qua... | |
/conference-highlights/aua-202... | AUA 2025: Impact of Prior Holmium Laser Enucleation of the Prostate (HoLEP) on the Accuracy of PI-RADS for Assessing Clinically Significant Prostate Cancer | |
/conference-highlights/aua-202... | View all AUA 2025 coverage | |
/conference-highlights/ses-aua... | Kein Text | |
/conference-highlights/ses-aua... | SES AUA 2025: Artificial Intelligence Applications in Prostate Cancer Diagnosis and Treatment | |
/conference-highlights/ses-aua... | SES AUA 2025: Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel Accounting for Subsequent Ther... | |
/conference-highlights/ses-aua... | SES AUA 2025: Early Longitudinal Outcomes of Black Men Undergoing PSA Screening Following Implementation of a PSA-Based Risk Stratification Algorithm in a He... | |
/conference-highlights/ses-aua... | View all SES AUA 2025 coverage | |
/library-resources/advanced-bl... | The Quickly Evolving Treatment Landscape of Metastatic Urothelial Carcinoma: A New Standard of Care in First-Line Systemic Therapy | |
/library-resources/advanced-bl... | The Treatment Landscape of Metastatic Urothelial Carcinoma: Second-Line Systemic Therapy | |
/center-of-excellence/advanced... | View all Advanced Bladder Cancer | |
/library-resources/m0-prostate... | Beyond a VISION to Making a SPLASH: Advances in PSMA-Based Theranostics in Prostate Cancer | |
/center-of-excellence/psma-tar... | View all PSMA-Targeted Therapy | |
/conference-highlights/aua-202... | AUA 2025: Ultra-low PSA Response (0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes | |
/conference-highlights/aua-202... | Trivialer Linktext Read More | |
/conference-highlights/aua-202... | AUA 2025: An Update on QUILT-3.032: Complete Responses to N-803 plus BCG Therapy in BCG-Unresponsive Bladder Carcinoma In Situ (CIS) with or without Ta/T1 Pa... | |
/conference-highlights/aua-202... | Textduplikat | Trivialer Linktext Read More |
/conference-highlights/aua-202... | CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the A... | |
/conference-highlights/aua-202... | Textduplikat | Trivialer Linktext Read More |
/conference-highlights/asco-gu... | ASCO GU 2025: Darolutamide Monotherapy in Patients with CSPC after Biochemical Recurrence: ARAMON Lead-in Phase Results | |
/conference-highlights/asco-gu... | Textduplikat | Trivialer Linktext Read More |
/about-urotoday.html | About UroToday | |
/heading-journal.html | Journals | |
/calendar.html | Calendar | |
/editorial-and-advertising-gui... | Editorial and Advertising Guidelines | |
/editorial-leadership.html | Editors and Contributors | |
/frequently-asked-questions-fa... | FAQs | |
/privacy-policy.html | Textduplikat | Privacy Policy |
/terms-of-use.html | Terms of Use | |
https://www.facebook.com/UroTo... | Extern Subdomain | Kein Text |
https://twitter.com/urotoday | Extern | Kein Text |
https://www.linkedin.com/compa... | Extern Subdomain | Kein Text |
/my-profile/lostpassword.html | Forgot Password? | |
/register.html | Textduplikat | Sign Up Free |
Name | Wert |
---|---|
date | Tue, 13 May 2025 05:03:34 GMT |
content-type | text/html; charset=utf-8 |
p3p | CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM", CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM" |
expires | Wed, 17 Aug 2005 00:00:00 GMT |
pragma | no-cache |
cache-control | no-store, no-cache, must-revalidate, post-check=0, pre-check=0, no-cache |
set-cookie | 91 Zeichen |
last-modified | Tue, 13 May 2025 05:01:58 GMT |
etag | "a1f6001601f59c18fb9aa100dfaa0070-gzip" |
vary | Accept-Encoding |
content-encoding | gzip |
x-content-type-options | nosniff |
cf-cache-status | DYNAMIC |
server | cloudflare |
cf-ray | 93ef9c2d5f323772-CDG |
alt-svc | h3=":443"; ma=86400 |
statuscode | 200 |
http_version | HTTP/2 |
# If the Joomla site is installed within a folder such as at # e.g. www.example.com/joomla/ the robots.txt file MUST be # moved to the site root at e.g. www.example.com/robots.txt # AND the joomla folder name MUST be prefixed to the disallowed # path, e.g. the Disallow rule for the /administrator/ folder # MUST be changed to read Disallow: /joomla/administrator/ # # For more information about the robots.txt standard, see: # http://www.robotstxt.org/orig.html # # For syntax checking, see: # http://www.sxw.org.uk/computing/robots/check.html User-agent: * crawl-delay: 10 Allow: /*.js* Allow: /*.css* Allow: /*.png* Allow: /*.jpg* Allow: /*.gif* Disallow: /SimpleSignOn.modal Disallow: /*.raw$ User-agent: Googlebot User-agent: Googlebot-News crawl-delay: 10 Disallow: /categories/1956-video-transcripts*.html Disallow: /uij-archives/1956-video-transcripts*.html Disallow: /component/content/category/1956-video-transcripts Disallow: /*/1228-conferences*.html Disallow: /*/1964-library-resources*.html Disallow: /administrator/ Disallow: /cache/ Disallow: /cli/ # Don't want to index these because of duplicate content and 404s Disallow: /SimpleSignOn.modal Disallow: /*.raw$ Disallow: /includes/ Disallow: /installation/ Disallow: /language/ Disallow: /libraries/ Disallow: /logs/ Disallow: /tmp/ Disallow: /usr/local/apache/htdocs/ Disallow: /usr/bin/php User-agent: Googlebot-Image crawl-delay: 10 Allow: /images/ Allow: /media/ User-agent: Mediapartners-Google crawl-delay: 10 Disallow: /administrator/ Disallow: /cache/ Disallow: /cli/ Disallow: /includes/ Disallow: /installation/ Disallow: /language/ Disallow: /libraries/ Disallow: /logs/ Disallow: /tmp/ Disallow: /usr/local/apache/htdocs/ Disallow: /usr/bin/php # JSitemap entries Sitemap: http://www.urotoday.com/index.php?option=com_jmap&view=sitemap&format=xml Sitemap: http://www.urotoday.com/index.php?option=com_jmap&view=sitemap&format=images # Sitemap: http://www.urotoday.com/index.php?option=com_jmap&view=sitemap&format=mobile Sitemap: http://www.urotoday.com/index.php?option=com_jmap&view=sitemap&format=gnews #User-agent: msnbot #Disallow: / #User-agent: Yandex #Disallow: / User-agent: Baiduspider User-agent: Naver User-agent: Majestic-12 User-agent: Majestic-SEO User-agent: Slurp User-agent: AhrefsBot User-Agent: MJ12bot Disallow: / User-Agent: SEMrushBot-Desktop crawl-delay: 10 Disallow: /SimpleSignOn.modal Disallow: /*.raw$ # [email protected] may 8th 2025 # # # Amazon Bot - enabling Alexa to answer even more questions for customers. User-agent: Amazonbot Disallow: / # Anthropic AI Bot User-agent: anthropic-ai Disallow: / # Apple Bot - collects website data for its Siri and Spotlight services. User-agent: Applebot Disallow: / # Claude Bot run by Anthropic User-agent: Claude-Web Disallow: / # Cohere AI Bot - unconfirmed bot believed to be associated with Cohere’s chatbot. User-agent: cohere-ai Disallow: / # Common Crawl's bot - Common Crawl is one of the largest public datasets used by AI for training, with ChatGPT, Bard and other large language models. User-agent: CCBot Disallow: / # Diffbot - somewhat dishonest scraping bot used to collect data to train LLMs. User-agent: Diffbot Disallow: / # ImagesiftBot is billed as a reverse image search tool, but it's associated with The Hive, a company that produces models for image generation. User-agent: ImagesiftBot Disallow: / # KUKA's youBot User-agent: YouBot Disallow: / # OMGilibot - They sell data for training LLMs (large language models) User-agent: omgilibot Disallow: / # Omgili (Oh My God I Love It) User-agent: omgili Disallow: / # OpenAI API - bot that OpenAI specifically uses to collect bulk training data from your website for ChatGPT. User-agent: GPTBot Disallow: / # Perplexity AI User-agent: PerplexityBot Disallow: / ## Social Media Bots # Bytespider is a web crawler operated by ByteDance, the Chinese owner of TikTok User-agent: Bytespider Disallow: / # Meta’s bot that crawls public web pages to improve language models for their speech recognition technology User-agent: FacebookBot Disallow: /
Folgende Keywords wurden erkannt. Überprüfe die Optimierung dieser Keywords für Deine Seite.
Keyword | Ergebnis | Prüfen |
---|---|---|
Urology | 68% | Check |
GU Oncology | 64% | Check |
Oncology | 63% | Check |
Urology GU Oncology | 63% | Check |
Monotherapy or | 54% | Check |
Urology Clinics | 54% | Check |
or Chemotherapy | 54% | Check |
or Metastatic Urothelial Cancer | 52% | Check |
Urologic Oncology | 51% | Check |
Advanced or Metastatic | 51% | Check |
PSMA PET CT | 51% | Check |
2025 coverage | 51% | Check |
Roger Li | 50% | Check |
PET CT | 50% | Check |
Cancer | 49% | Check |
Bladder | 49% | Check |
Bladder Cancer | 49% | Check |
PSMA | 49% | Check |
Advanced Bladder Cancer | 49% | Check |
PSMA 2025 | 49% | Check |
Bladder Cancer Treatment | 49% | Check |
Bladder Cancer AUA | 49% | Check |
Advanced or Metastatic Urothelial | 49% | Check |
ASCO GU | 49% | Check |
Prostate Cancer | 48% | Check |
Bitte wähle eine der Optionen.
Kontakt-Optionen
Schreibe eine Email an [email protected]
Rufe uns an unter +49 911 23756261
Mo-Fr
9 bis 17 Uhr
Weitere Hilfe findest Du im Erste Schritte Guide,
oder besuche unsere FAQ, unser Wiki oder unseren Blog.
Bitte wähle eine der Optionen.
Wir haben Deine Nachricht erhalten und werden sie sobald wie möglich bearbeiten.
Wir verwenden Cookies, damit unsere Website funktioniert und auch für Analyse- und Werbezwecke. Du kannst optionale Cookies selbstverständlich auch deaktivieren, siehe die folgenden Links für weitere Informationen.
Diese Cookies werden für grundlegende Websitefunktionen benötigt.
Damit wir besser verstehen, wie Besucher unsere Website nutzen.
Damit wir für Dich passgenaue Angebote bereitstellen können.
(Nice to have)